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Chronic bilateral renal denervation has been shown in clinical and experimental studies to 
reduce systemic blood pressure in resistant hypertension, along with protective effects on the 
kidney. However, the role of bilateral renal denervation in the setting of diabetic nephropathy 
has not been investigated. The aim of this study was to explore the role of bilateral renal 
denervation on structural changes in the kidney, in an animal model of diabetic nephropathy. 
Transgenic, renin-overexpressing (mRen-2)27 rats were treated with streptozotocin to induce 
diabetes, resulting in hypertensive, diabetic rats, to allow the aetiology of diabetic nephropathy 
to occur. After 12 weeks, the rats were sacrificed, and the renal tissue used in a range of 
molecular techniques to establish changes in molecular markers of renal injury and fibrosis.  
Denervation was confirmed with analysis of noradrenaline in the renal tissue, which was 
significantly decreased by denervation in both normoglycaemic and diabetic animals. Diabetic 
tissue showed higher levels of noradrenaline, signifying an increased level of renal sympathetic 
nerve activity, which supported the hypothesis that an increase in renal sympathetic nerve 
activity results in renin-angiotensin system activation, and renal injury. Diabetic, innervated 
rats showed lower levels of podocin, indicating glomerular injury, and this was restored by 
denervation to normoglycaemic levels. Collagen I and collagen IV expression were both 
increased in diabetic, innervated kidney tissue, and this was also reduced by denervation. 
Angiotensin II type 1 receptor expression was increased in the renal tissue, indicating renin-
angiotensin system activation, which would cause further renal damage and deterioration.  
The study concluded that bilateral renal denervation is a potential method in which to reduce 
the detrimental effects on the kidney in an animal model of diabetic nephropathy, through the 
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1.1 Review of Renal Structure and Function 
 
1.1.1 Renal Function 
Maintaining a homeostatic balance of water, electrolytes, as well as an acid-base balance, is a 
crucial function of the human body, and many systems are involved, including the renal system. 
Changes in dietary sources of water and electrolytes, as well as varying metabolism and usage, 
result in a fluctuating plasma osmolarity and volume. Such changes in blood volume must be 
controlled, or blood pressure can be adversely affected, resulting in cardiovascular 
complications such as microvascular injury and atherosclerosis. Increased osmolarity, often 
caused by elevated amounts of sodium in the plasma, will subsequently increase the blood 
volume to bring the osmolarity back into the homeostatic range. However, an increased blood 
volume within the same confines of the vasculature must therefore raise the blood pressure. 
Thus the renal system functions to reduce blood volume when needed, by allowing any excess 
water and electrolytes to be removed from the blood in the eventual production of urine. This 
role in osmoregulation of the blood in turn allows osmotic regulation of all other organs (Marieb 
and Hoehn, 2007; Thibodeau and Patton, 2007; Koeppen and Stanton, 2006).  
In humans, kidneys are normally bilaterally located in the upper retroperitoneal area, with all 
renal blood vessels and the ureters entering and exiting through the hilum. The general structure 
of the kidney (Figure 1) is comprised of a cortex around the outer edge, with a medulla made 
up of medullary pyramids in the centre. The pyramids drain though minor and major calyces 
into the renal pelvis, which then feeds out to the ureter.  The average human kidney is made of 
several lobes, which fuse together by adulthood. A fibrous capsule covers the entire kidney and 
a thick layer of perinephric fat protects the kidney from damage (Marieb and Hoehn, 2007; 





Figure 1: Schematic representing coronal kidney section. A – Renal capsule; B – Cortex; C – 
Medulla;  D – Renal hilum; E – Renal pyramid; F – Minor calyx; G – Major Calyx; H – Renal 
pelvis; I – Ureter; J – Renal artery; K – Interlobular artery; L – Interlobular vein; M – Renal 
vein; N – Renal column; O – Renal papilla; P – Nephron. Schematic downloaded from stock 
image website Pixabay.com (free download and no author attribution required). Information 
added to schematic collated from Marieb and Hoehn, 2007; Thibodeau and Patton, 2007; 
Koeppen and Stanton, 2006. 
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1.1.2 Nephron Structure and Function 
The individual functional and structural units of the kidney are composed of nephrons, of which 
there are approximately one million in each healthy human kidney (Zandi-Nejad et al., 2006), 
with studies into glomerular numbers describing a range from as low as 0.2 million up to 1.8 
million (Hughson et al., 2003). The nephron (Figure 2) consists of the renal corpuscle, which 
controls filtration of the plasma, and the renal tubule, which selectively reabsorbs water and 
electrolytes from the glomerular filtrate (Nishimura and Fan, 2003). Blood passes through the 
glomerulus in a series of anastomosing capillaries within the Bowman’s capsule (Miyoshi, 
1978). It is here that water and other low-molecular weight components of plasma are filtered 
through the filtration barrier to form the ultrafiltrate (Koushanpour and Kriz, 1986), and this 
structure can significantly deteriorate in relation to age (Tan et al., 2010) and other disease 
states. This ultrafiltrate is then passed through the renal tubules, beginning with the proximal 
convoluted tubule, which is responsible for most water and electrolyte reabsorption, as well as 
waste product and drug elimination (Neumann and Rector, 1976). The filtrate then flows 
through the loop of Henle, which is made up of descending thin, and then thick ascending limbs, 
and is mainly involved in generating high osmotic pressure in the extracellular fluid of the 
medulla, which is an essential component of the formation of concentrated urine. The Na+/Cl- 
transporters located primarily in the thick limb of the loop of Henle allow control of 
reabsorption of NaCl, thus regulating the osmotic pressure in the fluid of the medulla (Imai et 
al., 1987). Continuing on from the loop of Henle is the distal convoluted tubule that actively 
reabsorbs sodium ions, before the filtrate passes through the collecting tubule. The point at 
which the thick ascending loop of Henle becomes the distal convoluted tubule sits in close 
proximity to its respective nephron, and contains the macula densa. This thickened layer of 
specialised intimal cells samples the Na+/Cl- concentration of the distal tubule and forms a 
tubuloglomerular feedback loop involving adenosine and prostaglandin synthesis and release 
to control renin secretion by the juxtaglomerular cells lining the adjacent afferent arteriole. 
Activation of this tubule glomerular feedback pathway releases vasoconstrictive substances to 
control glomerular pressure and regulate glomerular filtration rate (Schnermann et al., 1973). 
Several mediators such as the renin-angiotensin pathway and endothelin release are involved 
with the regulation of this feedback system, with nitric oxide synthase shown to have a 
vasodilatory effect (Wilcox et al., 1992). Downstream from the distal convoluted tubule are 
collecting ducts, several of which converge to form a collecting duct, delivering the filtrate into 
the ureter as urine (Kriz, 1981). 
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Heilman and co-workers, used magnetic resonance imaging (Heilmann et al., 2012) to establish 
that rat models possess a similar nephron structure, albeit with a reduced number of nephrons 




Figure 2: Schematic representing the nephron structure. Schematic purchased from Adobe 
Stock online (no author attribution required). Information added to schematic collated from 
Marieb and Hoehn, 2007; Thibodeau and Patton, 2007; Koeppen and Stanton, 2006. 
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1.1.3 Renal Vasculature 
Renal arteries branch from the abdominal aorta just below the superior mesenteric artery, and 
enter the kidney through the hilum via two main branches. The posterior branch passes behind 
the renal pelvis to the posterior side of the kidney. The anterior branch branches into four 
anterior segmental arteries, described as the apical and lower segmental arteries, which 
vascularise the posterior and anterior upper and lower kidney, and the upper and middle 
segmental arteries which supply the rest of the anterior kidney. These vessels pass through the 
renal sinus and branch out to lobular arteries, becoming interlobular arteries whilst passing 
between renal pyramids, becoming arcuate arteries and creating a highly vascularised renal 
cortex. The arcuate arteries eventually lead to the afferent arterioles of the glomerulus, from 
which efferent arterioles drain filtered blood back through a venous system similar to the 
arterial system (Elger et al., 1997). Arcuate veins drain the renal cortex and feed into interlobar 
veins, and eventually the renal vein which exits again through the hilum, to connect with the 
inferior vena cava (Urban et al., 2001; Marieb and Hoehn, 2007; Thibodeau and Patton, 2007; 
Koeppen and Stanton, 2006).  
Renal blood flow is a measure of blood delivered to the kidney per unit of time. In most healthy 
systems, renal blood flow comprises approximately 20-25% cardiac output (Gruskin et al., 
1970). Whilst many factors can influence renal blood flow, autonomic control is the major 
component involved, with sympathetic vasoconstrictors extremely effective at reducing renal 
blood flow, and release of sympathetic modulators from the adrenal gland serving to reinforce 
sympathetic vasoconstriction. Blood pressure could also be a factor in controlling renal blood 
flow, however autoregulation of blood pressure usually means that in a healthy system, vascular 
resistance will change to accommodate and control both blood pressure and renal blood flow. 
However, this is only over a certain range of pressure, as at extremely low or high pressures the 
vascular resistance cannot adjust enough, resulting in reduced or elevated renal blood flow.  
1.1.4 Renal Innervation 
Innervation of the kidneys involves nerves from various sections of the spinal cord. The renal 
plexus, formed from several different ganglia, including the celiac ganglia and the splanchnic 
nerves, describes the collection of post-ganglionic sympathetic nerves that innervate the kidney, 
travelling along arterial branches through the hilum of the kidney, and thus branching out to 
innervate the blood vessels, glomeruli, and tubules (Marieb and Hoehn, 2007; Koeppen and 
Stanton, 2006). The main sympathetic neurotransmitter involved in renal regulation is 
noradrenaline (NA), with co-neurotransmitters adenosine triphosphate and neuropeptide Y. The 
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kidney is innervated by primary sensory neurons which are mainly B-type primary afferents 
that become unmyelinated C and myelinated Aδ fibres.  
Renal innervation plays an important role in the overall function of the kidney, with 
considerable control exerted from sympathetic nerves over both renal blood flow and the 
glomerular filtration rate. Whilst the afferent and efferent arterioles both have sympathetic 
innervation, the level of sympathetic tone is low with a normal extracellular fluid volume. When 
activated, the noradrenaline released from these sympathetic nerves combines with 
noradrenaline from the adrenal medulla to cause vasoconstriction of these afferent arterioles, 
via α-adrenoceptors, and this reduces the rate of filtration through the kidney, as well as the 
total renal blood flow. This can be useful in a fight or flight scenario, or to preserve arterial 
pressure in a haemorrhage situation, but is also seen in diseases such as the nephropathy 
observed in diabetes, and can lead to a sustained reduction in overall kidney function (Koeppen 
and Stanton, 2006). Renal innervation also plays an important role in the development of 
hypertension, with studies suggesting elevated renal sympathetic activity in renovascular 
hypertension (Johansson 1999).     
1.1.5 Renal Filtration Barrier 
A key component in the renal maintenance of water and electrolyte homeostasis is the original 
filtration of the plasma and blood. This occurs in the glomeruli, within the Bowman’s capsule, 
as the blood passes through a series of anastomosing capillaries. Water and other molecules are 
drawn out of the plasma through a filtration barrier to form the ultrafiltrate. The filtration barrier 
is comprised of three components named the fenestrated capillary endothelium, the glomerular 
basement membrane, and the podocytes (Tryggvason and Pettersson, 2003).  
1.1.5.1 Fenestrated Capillary Endothelium 
The first barrier through which plasma must filter through is the fenestrated capillary 
endothelium. This is a specialised layer of endothelial cells that has larger fenestrations between 
cells (70-100 nm in diameter) allowing large molecules to pass through into the filtrate, whilst 
a negatively charged luminal surface blocks the passage of any anionic molecules. The rate of 
filtration is therefore dependent on the number of fenestrations, and is important in preventing 
the filtration of proteins. Kidney diseases which present with proteinuria (protein detected in 
the urine) often have dysfunctional glomerular endothelial cell fenestrations among other 
molecular complications (Marieb and Hoehn, 2007; Thibodeau and Patton, 2007; Koeppen and 
Stanton, 2006).    
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1.1.5.2 Glomerular Basement Membrane 
Once through the layer of endothelium, molecules must pass through a thick glomerular 
basement membrane that consists of collagen IV fibres, glycoproteins such as fibronectin and 
laminin, and proteoglycans. Studies using electron microscopy have revealed three distinct 
layers in the basement membrane, and the mesh network formed by one of these layers blocks 
any larger molecules (Koeppen and Stanton, 2006).    
1.1.5.3 Podocytes 
Finally the plasma passes through a layer of specialised cells called podocytes. Podocytes are 
highly differentiated cells with long primary foot processes that attach to the capillary 
endothelium and diverge to form secondary foot processes or pedicels. It is these secondary 
foot processes that are mainly involved in the filtration barrier, by creating a slit diaphragm 
between foot process attachments through which molecules can filter (Marieb and Hoehn, 2007; 
Thibodeau and Patton, 2007; Koeppen and Stanton, 2006). The slit diaphragm size, which is 
typically around 40 nm wide, dictates the size of molecules that can fit through into the filtrate 
and is dependent on various proteins within the podocytes, including podocin and nephrin.  
Podocin is expressed in all glomerular podocytes and has been shown by immuno electron 
microscopy to be localised to the foot process near the insertion site of the slit diaphragm where 
it accumulates. Podocin works by interacting with nephrin, as well as a binding partner of 
nephrin known as CD2AP, thus contributing to the structural arrangement of the slit diaphragm 
(Schwarz et al., 2001). This protein can therefore be used as an experimental marker of 
glomerular function, with a decrease in podocin indicating a lack of control on the slit 
diaphragm, thus causing widening of the slit diaphragm and therefore a deterioration of 
glomerular filtration.  
Nephrin is a transmembrane protein which interacts with podocin to create efficient signalling 
through nephrin in the adjustment of the slit diaphragm. An increased expression of either of 
these proteins indicates narrowing of the slit diaphragm and therefore a more specific filtering 
system (Gil-Bernabe et al., 2012). The other main function of the slit diaphragm is to create 
control over water flow because the large molecules which cannot pass through the diaphragm, 
such as albumin, create colloidal osmotic pressure which then holds back water molecules.  
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1.1.6 Glomerular Filtration Rate 
A common method of assessing the glomerular function is by measuring glomerular filtration 
rate (GFR), defined as the volume of fluid filtered from the plasma into the Bowman’s capsule. 
By measuring the level of chemicals that remain steady in the plasma and are completely 
filtered in the glomerulus, the rate of filtration can be determined. Inulin is a compound, which 
can be injected into the body and is neither reabsorbed nor secreted by the kidney, so the 
filtration of inulin is directly proportional to the filtration of water and solutes through the 
glomerulus. It is more common, however, to measure the clearance of creatinine, a by-product 
of muscle activity, which is produced naturally by the body and is also completely filtered by 
the glomerulus (Levey et al., 2009). Renal damage will usually affect the GFR and can thus be 
detected by measuring a patients’ GFR (Peralta et al., 2011).  Some studies have suggested that 
other measures of glomerular dysfunction and worsening renal function, such as serum cystatin 
C, are more accurate than the typical creatinine clearance test in cases of type 1 diabetes (Peralta 
et al., 2011; Premaratne et al., 2008).  
1.1.7 Renin-Angiotensin System  
Guyton et al., proposed in 1972 that blood pressure was regulated by a hormonal feedback 
system called the renin-angiotensin system (Figure 3). This endocrine regulatory system begins 
with the activation of juxtaglomerular cells, located in renal afferent arterioles at the 
juxtaglomerular complex, which secrete renin into the bloodstream in response to low blood 
pressure (detected by intrarenal baroreceptors), low Na+ detected by NKCC2 transporters in the 
macula densa, and by beta (β1) adrenergic receptor signalling in the juxtaglomerular cells. 
Enzymatic activity by renin causes the hepatic peptide, angiotensinogen, to be cleaved into 
angiotensin I in the immediate circulation. Angiotensin I is converted in the blood into 
angiotensin II by the angiotensin-converting enzyme (ACE) on the endothelial surface. It is this 
peptide angiotensin II that exerts vasoconstrictive effects on the vasculature, thus causing an 
increase in blood pressure (Guyton et al., 1972).  
There are two receptors upon which angiotensin II acts, known as the angiotensin II type 1 
receptor (AT1R), and the angiotensin II type 2 receptor (AT2R) (Gasparo et al., 2000). Whilst 
the most studied receptor for angiotensin II is the AT1R, the AT2R is less well researched, and 
seems to be present more in the foetal kidney and intestine than in adult. Most studies agree 
that the AT1R is important in renal function, although the AT2R is also involved, with studies 
showing potential roles in programmed cell death, or apoptosis (Yamada et al., 1996). However 
much renal research is focussed on the AT1R. Activation of the AT1R, a Gq/Gi-protein coupled 
receptor (Ohyama et al., 1992; Eguchi and Inagami, 2000; Zou et al., 2004), results in various 
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cardiovascular effects including the generation of arrhythmias after ischaemic episodes, with 
studies showing early afterdepolarisations were induced by angiotensin II application, and this 
induction was inhibited by blockers of the AT1R (Zhao et al., 2011). Other studies have 
investigated the role of the AT1R in development of atrial fibrillation, with literature suggesting 
that atrial fibrillation activates the AT1R which then leads to an increase in profibrotic markers 
and deposition of collagen (He et al., 2010). Vasoconstriction is also known to be caused by 
activation of the AT1R (Yang et al., 2008) in various blood vessels around the body, including 
the coronary arterioles (Kushibiki et al., 2007). Activation of this receptor also increases the 
peripheral noradrenergic activity, causing an increase in vascular tone, thus decreasing blood 
pressure (Marcus et al., 2010). This is not just at a local level, but also in a central manner, with 
a study in renovascular hypertensive rats showing an increased level of activation in AT1R in 
the paraventricular nucleus in the brain resulted in an elevated level of renal sympathetic 
activity, which was reduced by treatment with an AT1R antagonist called losartan (Chen et al., 
2011). This constriction of blood vessels also reduces renal blood flow, which can damage the 
kidney. Angiotensin II also causes the release of aldosterone from the adrenal cortex which then 
acts on the tubules of the kidneys nephrons to increase sodium and water reabsorption (Marieb 
and Hoehn, 2007; Thibodeau and Patton, 2007; Koeppen and Stanton, 2006). The coupled 
effects of increased vascular constriction (also known as vascular resistance) and increased 
blood volume results in an elevation of blood pressure. This is an important factor in the 
maintenance of blood pressure. In hypertension however, this regulatory system becomes 
unbalanced (although the original cause is still debated), and the continual activation of the 
renin-angiotensin system results in uncontrolled hypertension (Crowley et al., 2006), leading 
to further complications, including atherosclerosis (Takaya et al., 2006), kidney damage (Zhang 





Figure 3. Renin-angiotensin system activation pathway. Information for figure collated from 
Guyton et al., 1972; Gasparo et al., 2000; Yamada et al., 1996; Yang et al., 2008; Marieb and 
Hoehn, 2007; Thibodeau and Patton, 2007; Koeppen and Stanton, 2006. 
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Diabetes mellitus is a condition characterised by the body’s inability to use glucose due to either 
lack of insulin or a lack of sensitivity to insulin. A cell needs glucose to carry out cellular 
functions and will eventually die if starved of glucose. Glucose deprivation in cardiac myocytes 
has been shown to induce the production of reactive oxygen species, and stimulate aggresome 
formation, as well as activating the process of autophagy (Marambio et al., 2010). The 
combination of increased oxidative stress and increased autophagy results in cell damage and/or 
death.  
1.2.2 Prevalence of Diabetes 
Diabetes has rapidly emerged as one of the most significant diseases of developed countries. A 
study by Stokes and Preston, 2017, assessed the relationship of increasing adiposity to an 
increased prevalence of diabetes in the United States of America, between 1988 and 2014. They 
found that the chances of having diabetes increased at a rate of 2.6%/year during that time 
period, with an adjusted prevalence of diabetes of 12.3% in 2014, having risen from 7.4% in 
1988, with the vast majority of these cases due to adiposity (Stokes and Preston, 2017).Another 
large study by King et al., 1998, investigated the prevalence of diabetes in the adult population 
(≥20 years of age) of all countries, for 1995, and projected prevalence for 2000, and 2025. This 
study predicted by 2025 that the prevalence of diabetes in New Zealand would increase from 
2.5% of the population in 1995 to 3.2% in 2025 (King et al., 1998). A study in 2004 looked at 
current rates of diabetes and extrapolated these to predict the prevalence in 2030, based on a 
static rate of obesity. It was predicted that the worldwide prevalence would be 4.4%, an increase 
from the worldwide prevalence in 2000 of 2.8%, and this prediction was expected to be an 
underestimation as obesity rates remain on an increasing trend (Wild et al., 2004). Danaei et 
al., 2011, showed an increase from 153 (127-182) million people with diabetes in 1980, to 347 
(314–382) million people in 2008. Research published in the New Zealand Medical Journal in 
2013 looked at rates of diabetes in New Zealand. Data from the New Zealand Adult Nutrition 
Study, a cross-sectional study which involved 4721 New Zealanders above 15 years of age, was 
used to estimate rates of diabetes, undiagnosed diabetes, and pre-diabetes, with both declaration 
and HbA1c parameters used to define diabetic status. It was calculated that 7% of the population 
has diabetes, with 25.5% exhibiting pre-diabetes, and prevalence was higher among males and 
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obese people (Coppell et al., 2013). These increasing trends of diabetes seen throughout the 
world have led to the label of a ‘Diabetic Epidemic’, and underlie the increases seen in the 
incidences of complications arising from the condition. 
1.2.3 Glucose Uptake and Metabolism 
Glucose uptake occurs via two different mechanisms, the main way being via passive diffusion 
through transporters in the plasma membrane, a process dependent on a concentration gradient 
between the extracellular and intracellular compartments. The other process in which glucose 
enters the cell is via secondary active transport, which is indirectly an ATP-dependent process 
(Marieb and Hoehn, 2007; Thibodeau and Patton, 2007; Koeppen and Stanton, 2006). 
 In muscle and adipose cells, glucose is allowed to passively diffuse through the glucose 
transporter type 4 (GLUT4). Insulin binds to the insulin receptor and thence causes the 
translocation of GLUT4 to the plasma membrane. This allows glucose to enter through GLUT4 
into these high-energy cells. Therefore insulin is an essential part of cellular function in these 
cells (Konrad et al., 2001). Disruption of GLUT4 in male mice has been shown to result in 
insulin resistance and the development of diabetes, with no increase in obesity (Stenbit et al., 
1997). Although GLUT4 in muscle cells is the main factor involved in glucose metabolism, 
one study which used Cre/loxP DNA recombination to selectively reduce adipocyte GLUT4 
while leaving expression levels of muscle GLUT4 unaffected showed that insulin resistance 
still occurs, despite normal muscle cell glucose function (Abel et al., 2001).  
The secondary active transport mechanism occurs in the kidney, where the concentration 
gradient is such that passive diffusion is not an option, and functions to remove glucose from 
the filtrate and put it back into the blood system. In diabetes the lack of insulin or the 
insensitivity to insulin causes a build-up of glucose in the blood which cannot enter the cells as 
the key insulin step cannot take place, and thus a state of hyperglycaemia (high blood glucose) 
occurs whilst the cells essentially starve as no glucose can enter the cell. This is diagnosed by 
the presence of glucose in the urine, and reflects the inability of the kidney to take up glucose, 
resulting in glucose remaining in the filtrate (Marieb and Hoehn, 2007; Thibodeau and Patton, 
2007; Koeppen and Stanton, 2006).    
1.2.4 Type 1 Diabetes 
Type 1 diabetes occurs as the result of an autoimmune disorder, in which the immune cells of 
the body attack the pancreatic β-cells that produce insulin, with some evidence indicating the 
involvement of CD8 T cell immunoreactivity in this destruction of β-cells (Pinkse et al., 2005). 
These β-cells eventually lose all function, causing a lack of endogenous insulin. The deficiency 
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of insulin results in the development of diabetes mellitus with an increase of blood glucose 
coupled with the inability of cells to obtain glucose.  
This form of diabetes is treated with an analogue of insulin with careful monitoring of glucose 
intake, aiming for a tight glycaemic control. The inability to tightly control using a combination 
of short and long acting insulins to control blood glucose levels leads to significant swings 
between hypoglycaemia and hyperglycaemia, with both states becoming fatal without treatment 
(Barrett-Connor and Ferrara, 1998; Friedrich and Dougherty, 2004). The Diabetes Control and 
Complications Trial (DCCT) investigated the outcomes of intensive or conventional therapy, 
with intensive therapy proving more beneficial in relation to cardiovascular complications 
(DCCT/EDIC, 2011). Intensive therapy involved insulin administration based on several blood 
glucose measurements per day, with strict targets of blood glucose to be kept, whilst 
conventional therapy involved less monitoring with a goal of merely avoiding hypoglycaemic 
or hyperglycaemic episodes (Nathan et al., 2005).   
1.2.5 Type 2 Diabetes 
Type 2 diabetes does not result from a lack of insulin but rather from consistently high blood 
glucose levels that have caused a reduction in the sensitivity of cells to insulin (Hotta et al., 
2001; Yang et al., 2005). As insulin is essential for glucose uptake, the cells are unable to gain 
glucose and essentially starve. Type 2 diabetes cannot be treated by insulin replacement in the 
initial stages of the disease as it is the action of insulin at the insulin receptor which is affected, 
and thus these patients are primarily treated with a diet and exercise management regime, 
coupled with oral hypoglycaemic medication such as metformin to increase insulin sensitivity 
and reduce hepatic gluconeogenesis (DPPRG 2002). In some patients the disease may progress 
such that the pancreas may be damaged and insulin supplementation is needed as well (UKPDS, 
1998).   
Research from the Women’s Health Study investigated the link between type 2 diabetes and 
expression of inflammatory markers (Pradhan et al., 2001). The Women’s Health Study 
involved 188 non-diabetic women from a larger cohort who developed diabetes over four years, 
and were compared with 362 healthy controls who were matched by both age and fasting status. 
Interleukin-6 is an integral pro-inflammatory cytokine, with C-reactive protein a downstream 
factor of interleukin-6 pathways. Both of these are known inflammatory markers, and have been 
shown to be involved somehow in patients with insulin resistance and type 2 diabetes. This 
study by Pradhan et al., 2001, revealed increased levels of C-reactive protein and interleukin-6 
predicted the development of type 2 diabetes. Women in the highest quartile of interleukin-6 
expression had a relative risk of development of type 2 diabetes of 7.5 (95% CI 3.7-15.4) 
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compared to those in the lowest quartile, with women in the highest quartile of C-reactive 
protein showing a similar trend, with a relative risk of 15.7 (95% CI 6.5-37.9) compared to 
those in the lowest quartile (Pradhan et al., 2001).  
Another study looked into the role of adiponectin, a circulating protein similar to collagen, in 
the Pima Indian population, a group with the highest rate of type 2 diabetes in all populations. 
70 patients who developed type 2 diabetes along with 70 controls were investigated. Increased 
levels of adiponectin are related to an increase in insulin sensitivity. The state of obesity has 
been shown to result in reduced levels of adiponectin, and obesity is a clear factor in the 
development of type 2 diabetes. Therefore, adiponectin is a potential factor involved in the link 
between obesity, insulin resistance, and type 2 diabetes (Lindsay et al., 2002).    
Similar to the destruction of β-cells in the pancreas of type 1 diabetics, the role played by these 
cells in type 2 diabetes has also been investigated. Pancreatic tissue was used from 124 
autopsies of Minnesota, USA population, with either lean or obese subjects with type 2 diabetes, 
impaired fasting glucose, or non-diabetic controls. Analysis of this tissue proved an increase in 
β-cells in obese patients vs. lean patients. However, the addition of type 2 diabetes results in a 
63% reduction in the number of β-cells in obese patients, and 41% reduction amongst lean type 
2 diabetics. This was backed up with an increase in β-cell apoptosis of three fold amongst obese 
type 2 diabetic tissue, and lean type 2 diabetic tissue showed a 10 fold increase in apoptosis of 
β-cells (Butler et al., 2003). A study published in 2005 (Yang et al., 2005) also investigated the 
link between obesity and type 2 diabetes, with results describing a role played by serum retinol 
binding protein 4 (RBP4) in the development of insulin resistance, with a gradual reduction in 
the expression of GLUT4 observed in adipocytes as type 2 diabetes develops. Serum retinol 
binding protein 4 is known primarily for transport of retinol from the liver to the periphery but 
it has also been described as an adipokine, or a signalling molecule from adipocytes. As a 
reduction of GLUT4 is seen in obesity and type 2 diabetes, a GLUT4 knockout mouse model 
was used to investigate RBP4, showing that levels of RBP4 are elevated in adipocytes of 
animals with no GLUT4. This was normalised by the administration of insulin-sensitising agent 
rosiglitazone. Genetic deletion of RBP4 has been shown to increase insulin sensitivity, as has 
the administration of fenretinide (a drug indicated to increase retinoid excretion) in obese mice, 
which improves insulin resistance and glucose intolerance. Insulin signalling was conversely 
impaired in muscles by the increased expression of RBP4. Retinol binding protein 4 has 
therefore an interesting role in the development of Type 2 diabetes with potential roles in 
interventional strategies (Yang et al., 2005).   
Treatments for type 2 diabetes aim to improve glycaemic control by improving insulin 
sensitivity. Control of blood glucose is known to reduce microvascular disease progression with 
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intensive therapy involving sulfonureas and insulin proving to reduce complications such as 
diabetic retinopathy, and other arteriosclerotic complications, whilst having no effect on 
cardiovascular outcomes (Stratton et al., 2000; Turner et al., 1998). The risk of complications 
arising from long term hyperglycaemia was also investigated in a study involving 4585 patients 
recruited throughout England, Scotland, and Northern Ireland. Improvements in glycaemic 
control resulted in improvement in clinical complications, with a 1% reduction in HbA1C 
(glycated haemoglobin) resulting in a 21% reduction of end-points related to diabetes (Stratton 
et al., 2000).  
The Finnish Diabetic Prevention Study, a study of 522 subjects at risk of type 2 diabetes 
(elevated body mass index and/or impaired glucose tolerance) over six years randomised 
individuals to either intensive individualised lifestyle programmes, or to general information 
on lifestyle. Intensive lifestyle changes prevented development of type 2 diabetes, with the 
overall risk of developing diabetes reduced by 58% (Tuomilehto et al., 2001). The FIELD study 
(Fenofibrate Intervention and Event Lowering in Diabetes) of 9795 subjects with type 2 
diabetes used a multinational randomised control trial over five years to look at the effect on 
cardiovascular events that fenofibrate therapy exhibited. Total cardiovascular events were 
reduced by fenofibrate treatment, with reduced albuminuria progression, and improvements in 
retinopathy, along with a reduction in the number of non-fatal myocardial infarctions (Keech 
et al., 2005).  
1.2.6 Diabetic Complications 
Aside from the potential risks involved with fluctuating blood glucose levels, diabetes is also 
associated with several other serious problems which can develop into separate diseases.  
1.2.7 Diabetic Cardiomyopathy 
One major problem which can often develop as a result of diabetes is that of diabetic 
cardiomyopathy, a disease described as cardiomyopathy with no other apparent cause but the 
presence of diabetes in the patient. Ischaemic heart disease is a major cause of death in many 
developed countries and the association with diabetes has been clear for many years, with 
cardiovascular disease one of the primary causes of both morbidity and mortality in patients 
with diabetes noted as early as 1970 (Garcia et al., 1974). Diabetic cardiomyopathy is 
characterised by diastolic dysfunction and will progress to severe cardiac problems including 
heart failure (Basu et al., 2009).  Diabetic cardiomyopathy was first described in the literature 
in a study of post-mortem findings carried out on patients with confirmed diabetic 
glomerulosclerosis. Of the 27 patients, four were found to have cardiomegaly and congestive 
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heart failure without any obvious cause including hypertension, coronary artery disease, or 
valvular diseases. Further analysis of cardiac tissue revealed left ventricular hypertrophy and 
fibrosis, and with the absence of any other cause, this heart disease was characterised as diabetic 
cardiomyopathy (Rubler et al., 1972). Left ventricular diastolic dysfunction was described by 
several studies to be an early sign of diabetic cardiomyopathy, with even young insulin-
dependent diabetic patients with no apparent systolic dysfunction showing diastolic dysfunction 
including reduced diastolic filling, increased atrial filling, and longer times for isovolumetric 
relaxation and deceleration time (Schannwell et al., 2002).  
1.2.8 Diabetic Retinopathy 
Another significant disease seen in diabetes is diabetic retinopathy, with 28.5% prevalence of 
this disease found amongst diabetic adults in the USA (Zhang et al., 2010), in which the 
consistently high blood glucose levels causes proteins in the eyes retina to become glycated. 
The high glucose levels cause activation of pro-apoptotic pathways in the pericytes of the retinal 
capillaries, resulting in increased permeability of the retinal blood vessels and thus bleeding 
into the retina, permanently damaging sight. Vascular endothelial growth factor is involved in 
the angiogenesis important in this disease (Adamis et al., 1994), and erythropoietin derived 
peptide treatment of streptozotocin-induced diabetic rats was shown to reduce the apparent 
damage in this disease (McVicar et al., 2011).  
Whilst these diseases are common in diabetic patients, there is another frequently associated 
condition of diabetes on renal structure and function which is extremely debilitating. This is 
known as diabetic nephropathy (DN) and is the current focus of a great deal of research, 
including this thesis.  
1.2.9 Diabetic Nephropathy  
Diabetic nephropathy is a serious and progressive renal disease caused by diabetes mellitus 
(Ritz et al., 1999). With an increasing burden of diabetes becoming apparent in many developed 
countries, DN is also increasing in incidence and clinical relevance. From early studies which 
described DN as a major cause of death in patients with type 1 diabetes (Andersen et al., 1983), 
DN has been known to be as important as cardiovascular disease in the condition of diabetes. 
Employing a follow up study of 1475 type 1 diabetic patients recruited in Denmark and 
followed until either death or 25 – 40 years, this study reported DN in 41% patients, with 21% 
prevalence after 20 – 25 years of diabetes. It was also clear that DN resulted in an increased 
chance of death, with results showing that after 40 years of diabetes, only 10% of those who 
developed nephropathy were alive, whilst 70% of those who had not developed DN were alive 
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still. Furthermore, after 7 years of DN (classified as persistent proteinuria), 49% of patients had 
died (Andersen et al., 1983). Another study in a Japanese population reported that the incidence 
of DN, whilst decreasing among type 1 diabetics, was increasing in type 2 diabetics (Yokoyama 
et al., 2000), with an incidence of 44.4% amongst type 2 diabetics compared to 20.2% amongst 
type 1 diabetics.  
1.2.10 Clinical Signs of Diabetic Nephropathy 
Diabetic nephropathy is characterised by a reduction in renal function progressing to renal 
failure, and clinically defined as worsening proteinuria accompanied by hypertension and 
glomerular dysfunction. Patients exhibit reductions in glomerular filtration, shown by the 
presence of glucose and proteins in urine, indicating disruption of both the glomerulus and the 
renal tubules. Long term intensive therapy of diabetes reduces the risk of development of an 
impaired glomerular filtration rate compared with conventional therapy regimes (UKPDS, 
1998).  Albuminuria and hypertension are classical symptoms of DN (Mauer et al., 1984), with 
DN classified definitively into two major stages by the urinary albumin to creatinine ratio 
(ACR), with microalbuminuria (ACR of 2.5 to 25.0 mg/mmol) and macroalbuminuria (ACR of 
25mg/mmol in males and ≥30 mg/mmol in females) (Johnson et al., 2012). As the nephron 
deteriorates, the degree of filtration becomes less, with larger molecules entering the filtrate, 
and the selectivity of filtration is reduced (Schjoedt et al., 2004). Following the deterioration of 
glomerular filtration, the overall renal function worsens, resulting in eventual loss of renal 
function, necessitating dialysis awaiting renal transplant. Much research has therefore focused 
on understanding the underlying molecular functional and structural changes observed in these 
kidneys.  
The damage involved in DN occurs as a result of changes in haemodynamics, with an increase 
in blood pressure and intra-glomerular pressure leading to activation of the renin-angiotensin 
system. This continues to activate other messengers including growth factors and kinases 
(Soldatos and Cooper, 2008). Occurring in parallel with these changes is damage resulting from 
the high blood glucose associated with diabetes. Hyperglycaemia causes the development of 
reactive oxygen species. These activate glycation of various proteins, forming advanced 
glycation end products, which, along with cytokines and other growth factors, cause an increase 
in the formation and deposition of collagen in the extracellular matrix. This expansion of the 
extracellular matrix causes eventual sclerosis of the glomeruli and tubules, thus making the 
kidney inefficient (Alsaad et al., 2007; Soldatos and Cooper, 2008).  
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1.2.11 Histopathological Features of Diabetic Nephropathy 
Several histopathological features have been associated with DN. One sign observed early in 
the progression of the disease is thickening of the glomerular basement membrane, which 
classifies Class I of DN (Tervaert et al., 2010), with some studies reporting thickened 
glomerular basement membrane after only 1.5 – 2 years of type 1 diabetes (Caramori et al., 
2000), which was also paralleled by tubular membrane thickening. 
Another relatively early sign involves an increase in mesangial matrix deposition which causes 
mesangial expansion (Mauer et al., 1984), which defines class II of DN (Tervaert et al., 2010). 
One of the first morphological signs of renal damage (Alsaad et al., 2007), mesangial expansion 
is one of the most important factors in the loss of kidney function in DN (Steffes et al., 1989). 
The signalling molecule protein kinase C (PKC) is thought to be involved in the worsening of 
mesangial expansion and long term administration of a PKC β inhibitor resulted in attenuated 
mesangial expansion in type 2 diabetic mice, with reduced expression of extracellular matrix 
proteins such as collagen IV and transforming growth factor β (TGF-β) (Koya et al., 2000). 
Other studies have also found that short-term treatment (Sharma et al., 1996) as well as chronic 
treatment of diabetic mice with an anti-TGF-β antibody can reduce the level of mesangial 
expansion observed (Ziyadeh et al., 2000).  
The mesangium within the glomerulus contains specialised smooth muscle mesangial cells that 
regulate the flow of blood through the capillaries in the glomerulus, thus allowing regulation of 
blood filtration. Disruption of normal function of these results in a breakdown of the normal 
functioning of the nephron.  
Glomerular basement membrane thickening and mesangial expansion are both seen in all type 
1 diabetic patients with symptomatic renal dysfunction (Kanter, 2009). This gradual increase 
in glomerular basement membrane thickening and mesangial expansion is due to the deposition 
of extracellular matrix, with proteins such as collagen IV and fibronectin (Erensoy et al., 2004; 
Tervaert et al., 2010), and is sometimes known as diffuse glomerulosclerosis. This thickening 
of the glomerular basement membrane is usually followed by the development of characteristic 
nodular glomerulosclerosis which defines Class III of DN (Tervaert et al., 2010). These are also 
known as Kimmelstiel-Wilson nodules, named for the physicians to first describe DN, and the 
presence of these in DN have been characterised by early studies (Clarke Stout et al., 1993; 
Tervaert et al., 2010). These nodules increase in size and number as the disease progresses, and 
have been found to develop in patients with DN and a longer history of diabetes (Hong et al., 
2007).  
Another major step in the eventual development of DN is the presence of afferent and efferent 
arteriolar hyalinosis. This is the development of exudative lesions, which replace the smooth 
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muscle with immunoglobulins, fibrinogen, and albumin. Correlations between the degree of 
arteriolar hyalinosis and the degree of glomerulosclerosis have raised the possibility that the 
alterations in glomerular blood flow that can arise from these vascular lesions could be partially 
responsible for the damage to the glomerulus (Fioretto et al., 1995; Tervaert et al., 2010).  
The later stages of DN involve the breakdown of several regions of the nephron. The 
glomerular-tubular junction displays focal adhesions and obstructions, along with atrophied 
tubules. Fibrosis develops throughout the kidney, with glomerular cells key in this step 
(Brosius, 2008). Eventually the combination of glomerulosclerosis, tubular dysfunction, and 
continued deposition of collagen result in a sclerosed and fibrosed kidney, with significantly 
impaired function and few treatment options available aside from dialysis and transplant. 
Known as class IV of DN, patients with this level of disease will have a high degree of 
glomerulosclerosis, and this is classified as end-stage renal disease (Tervaert et al., 2010).  
Fioretto and Mauer, 2007, described three major categories of DN, beginning with Category C 
I, which describes the patients with either normal renal biopsies, or extremely mild changes in 
glomerular or renovascular function. An increase in proteinuria from around 15% to 50% takes 
the patient to Category C II, also known as Typical DN. These patients display established 
diabetic lesions with equal severity of glomerular, tubular, and arteriolar dysfunction. While 
this is the most typical picture of DN, there are some patients whose glomerular dysfunction is 
relatively mild in comparison to severe tubular and arteriolar damage. These cases fit into 
Category C III of atypical patterns of renal injury (Tamborlane et al., 2008). 
Renal dysfunction in diabetes can be specific to the type of diabetes. Whilst inflammation is 
common to both (Saraheimo et al., 2003), type 1 DN is characterised by glomerular lesions, 
with thickening of the glomerular basement membrane along with mesangial expansion, with 
the podocytes, interstitium, renal tubules, and vasculature affected later on in the disease 
progression. Type 2 DN however will have signs of kidney damage such as microalbuminuria 
or proteinuria without changes to the glomerular structure and may even not display tubular or 
arteriolar dysfunction until later in the disease process (Tervaert et al., 2010).  
Along with the structural changes described already, the development of fibrosis is a major 
cause of dysfunction in DN. The accumulation of fibroblasts and extracellular matrix deposition 
contributes to fibrosed and sclerosed tissue which is largely dysfunctional (Tervaert et al., 
2010). 
The damage from DN is significant, and often exacerbated by the presence of hypertension in 
patients as well, resulting in a complex condition (Van Buren et al., 2011). 
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1.2.12 Diabetic Nephropathy and the Renin-Angiotensin System 
The renin-angiotensin system is significantly involved in the deterioration of the kidneys in 
DN. As the activity of angiotensin II increases, mesangial cells and tubular epithelial cells 
undergo hypertrophy which further contributes to deteriorating function (Chawla et al, 2010). 
Along with these changes, the increasing activity of angiotensin II causes further 
vasoconstriction which consequently raises blood pressure (Crowley et al., 2006). This increase 
in blood pressure can further impact the microvasculature in the kidney, which again reduces 
function and impacts on the ability of the kidney to control blood pressure via the renin-
angiotensin system. As angiotensin II increases, the subsequent activation of the adrenal gland 
to release aldosterone also increases, and this causes further sodium and water reabsorption, 
both of which contribute further to the increase in blood pressure (Koeppen and Stanton, 2006).  
1.2.13 Current Treatments of Diabetic Nephropathy 
There are several different pharmacological interventions currently employed in the treatment 
of DN. However, all of these are only able to slow down the progression of the disease, with 
no treatment as yet available to halt the disease. Most of these interventions work by reducing 
the blood pressure and therefore improving kidney function, mainly through modulation of the 
renin-angiotensin system. 
Treatments for DN have focused on blocking parts of this RAS, using pharmacological agents 
including ACE-inhibitors such as ramapril, angiotensin receptor blockers (ARBs) such as 
candesartan that antagonise the AT1R, and aldosterone inhibitors such as spironolactone. 
ACE-inhibitors are commonly prescribed to patients with hypertension and/or signs of DN and 
work to inhibit the ACE, thus preventing the conversion of angiotensin I into angiotensin II, 
and stopping the eventual rise in blood pressure (Lacourcière et al., 2000; Niskanen et al., 2001; 
Parving et al., 2001b).  
As previously mentioned, the AT1R is believed to be involved in the cardiovascular effects of 
angiotensin II, playing a role in the generation of arrhythmias after ischaemic episodes, along 
with general vasoconstrictive effects (Zhao et al., 2011). Activation of this receptor is also 
thought to increase the peripheral noradrenergic activity, and reduced renal blood flow (Marcus 
et al., 2010). Angiotensin receptor inhibitors such as irbesartan block the AT1R to reduce the 
pathological effects of activation of this receptor, and can therefore be renoprotective in this 




1.2.14 Novel Treatments for Diabetic Nephropathy - Renal Denervation 
Renal denervation is a surgical technique investigated around 40 years ago and currently 
garnering more attention as a treatment for patients with resistant hypertension. Several studies 
in the 1970’s researched the effect of denervation on hypertension. A study by Bello-Reuss et 
al., 1975, reported an increase in diuresis and natriuresis in male Sprague-Dawley rats with 
unilateral renal denervation, effects that correlated with a reduction in mean arterial pressure of 
7 ± 3 mm Hg after denervation (Bello-Reuss et al., 1975). Another group found that the renal 
sympathetic nerves contribute significantly to the development of hypertension in a 
spontaneously hypertensive rat model, through an increase in sodium retention, although the 
role of these nerves in the maintenance of hypertension was thought not to be significant 
(Winternitz et al., 1980). This interrelationship between sodium handling and the renal 
sympathetic nerves was also investigated by several groups, showing in spontaneously 
hypertensive rats that an increasing sodium intake causes an increase in renal sympathetic nerve 
activity as well as anti-natriuretic effects (Koepke et al., 1985).  
These early studies led to interest in renal denervation as a way to reduce hypertension, with 
several groups investigating this in animal models of hypertension. It was reported that bilateral 
renal denervation in spontaneously hypertensive rats carried out 5 weeks after birth delayed the 
onset of hypertension in these animals, although the final rate of development and level of 
hypertension was unchanged (Liard, 1977). Animal studies have shown that denervation 
resulted in preserved kidney function with cyclosporine induced renal damage seen in changes 
to glomerular filtration rate and renal blood flow, effects which were prevented by renal 
denervation (Murray and Paller, 1986). Studies have shown that renal sympathetic nerve 
activity is elevated in DN (Nielson et al., 1999), which makes DN a potential candidate for 
treatment via renal denervation.  
1.2.15 Clinical Evidence in Hypertension 
Several clinical studies have been carried out in the last decade, concentrating on the potential 
use of renal denervation in patients with resistant hypertension. The two main studies into this 
at the time of our study had been the Symplicity HTN-1 and HTN-2 trials, carried out in patients 
with resistant hypertension using the Medtronic’s Symplicity RDN System.  
The Symplicity HTN-1 trial treated 153 patients in 19 centres in Australia, Europe, and the 
USA in an open-label proof of concept study, with mean age of the cohort being 57±11 yr, 39% 
women, 31% diabetic, and 22% with existing coronary artery disease. Resistant hypertension 
was classified as an elevated systolic blood pressure (≥160mmHg) despite treatment with three 
types of antihypertensive pharmacological agents, including one diuretic. Blood pressure was 
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then measured at baseline, 1, 3, 6, 12, and 24 months after the denervation surgery, and showed 
a reduction which extended greater than two years follow up, with no significant adverse events. 
The surgery was also reported to go without complications in 97% patients. The reported safety 
and efficacy of the treatment from this trial led the way to further studies into this potential 
treatment (Krum et al., 2014). A second trial by the Symplicity group first published in 2010 
investigated 106 individuals with resistant hypertension, using similar criteria as previously in 
the Symplicity HTN-1 trial, randomly assigning patients to either denervation with previous 
treatment, or previous treatment alone. Systolic blood pressure recordings were taken at 
baseline, and compared with the endpoint of six months after surgery. Blood pressure did not 
significantly alter in the control group, but was significantly reduced by 32/12 mmHg by 
denervation. After six months the denervated group were significantly lower than the control 
group in blood pressure, with a change of 33/11 mmHg observed. A reduction in blood pressure 
greater than 10 mmHg after six months was reported in 84% of patients who had undergone 
renal denervation, compared with only 16% controls. As in the previous Symplicity HTN study, 
there were no reported serious complications associated with the surgery (Esler et al., 2010).       
Since our study was started there has been a great deal of controversy over the efficacy of renal 
denervation in the treatment of hypertension, and the robustness of the Symplicity trials. This 
will be addressed in detail in the discussion. 
1.3 Aims  
This study aimed to investigate the expression levels of noradrenaline, podocin, collagen type 
I, collagen type IV, and angiotensin II type 1 receptor as markers of renal dysfunction in the 
kidney of a rat model of DN, through the use of molecular techniques including western 
blotting, immunohistochemistry, and ELISA. 
1.4 Hypothesis 
We hypothesised that bilateral renal denervation in hypertensive rats with diabetes induced 
through streptozotocin destruction of pancreatic β-cells would alleviate or attenuate the renal 
damage and signs of DN observed in these rats. This can be further separated into two 
hypotheses: 
1. That bilateral renal denervation would restore expression of molecular markers such as 
podocin, and reduce fibrotic collagen expression to normoglycaemic levels in the 
diabetic animals.  
2. That this protection imparted by the renal denervation would be a result of reduced 





2.1 Experimental Protocol 
The surgical work described here was conducted by Dr Yimin Yao as part of his PhD thesis, 
under the University of Otago Animal Ethics Committee approval (51/09). The subsequent 
analytical studies described here were conducted by myself as part of this MSc programme. 
The kidneys isolated from the animal studies described were prepared for use in various 
molecular studies including ELISA, immunohistochemical techniques, and western blotting to 
determine the molecular pathways involved in the use of renal denervation to treat DN. 
Chemicals were sourced from Sigma (Sigma, Vic, Australia), unless otherwise stated.  
2.1.1 Animals 
Female heterozygous transgenic (mRen-2)27 rats were developed from the cross of male 
homozygous transgenic rats (Sprague Dawley (SD) with overexpression of the mouse Ren-2 
gene (Mullins et al., 1990) with normotensive Hanover SD female rats. This formed a 
heterozygous rat with hypertension from birth as a result of the overexpression of the Ren-2 
gene, involved in the expression of renin (Merrill et al., 1996), and this was important as these 
rats need both hypertension and diabetes to display signs of DN. Only the female rats were used 
in our study as it has been documented that the male rats of this transgenic species develop 
malignant hypertension at an earlier stage and to a greater degree than females. The rats used 
displayed significant parameters of disease, with an increase in systolic blood pressure observed 
by week six (Yao et al., 2014). The homozygous transgenic breeders were provided by 
Associated Professor Darren J. Kelly, Department of Medicine, University of Melbourne, 
Australia (Kelly et al., 1998), and breeding was carried out at the Christchurch Animal Breeding 
Facility.  
2.1.2 Treatment Groups 
Animals were randomly allocated into one of four treatment groups (n=7-8) at five weeks of 
age, with a normoglycaemic sham, normoglycaemic bilateral renal denervation, diabetic sham, 
and diabetic bilateral renal denervation groups. Those allocated to either of the diabetic groups 
were administered streptozotocin made in citrate buffer at 55 mg/kg i.v. by tail vein injection 
at six weeks of age, with normoglycaemic animals administered the same volume of citrate 
buffer alone. Streptozotocin administration is an accepted practice of inducing experimental 
diabetes through the destruction of insulin producing β-cells in the pancreas (Like and Rossini, 
1976; Szkudelski, 2001). Hyperglycaemia was determined in the blood with a glucometer 
(Accu-Chek Performa®, Roche Diagnostics, Mannheim, Germany), and blood glucose 
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measured every two days in all animals. Blood glucose levels in the diabetic groups were 
controlled at 20-25 mM by daily administration of the intermediate-release insulin isophane s.c. 
(protophane Novo Nordisk Pharmaceuticals, NSW, Australia). Animals in the normoglycaemic 
groups received a fixed volume (0.1 ml, s.c.) of sterile saline. Isophane was prepared by diluting 
the isophane in sterile saline (1:5) and stored at 4°C. The daily dose (1-4 units) of isophane 
administered to each animal was titrated against the blood glucose level recorded using a dosing 
algorithm communicated by Dr J Hill and Prof Z. Endre, Christchurch School of Medicine (Yao 
et al., 2014). At 9, 12, and 15 weeks of age rats underwent either a sham or BRD surgery, with 
repeat denervation surgeries performed every three weeks to prevent regrowth of efferent nerve 
fibres as is common in rats receiving this surgery (Mulder et al., 2013). Rats were sacrificed at 
18 weeks of age, and kidneys harvested. The 12 week hyperglycaemia duration chosen in this 
experimental protocol was based on earlier data from Kelly’s group publications, showing that 
a significant degree of renal fibrosis would not be apparent until 12 weeks after the 
streptozotocin administration (Kelly et al., 1998). Metabolic studies including systolic and 
diastolic pressure, heart rate, urine flow rate, and water intake were measured at various 
intervals between five and 18 weeks of age (Yao et al., 2014) (Figure 4).  
 
Figure 4. Protocol timeline used in the study.  
2.1.3 Bilateral Renal Denervation 
The bilateral renal denervation technique selected exposed the kidney bilaterally from the 
dorsal side in order to minimise infection and organ trauma risk within the peritoneal cavity.  
The renal nerve bundles present at the abdominal aorta junction with renal artery through to the 
renal pelvis were identified using a stereoscopic surgical microscope. Blanching of the kidney 
following nerve bundle stimulation using a bipolar stimulating electrode (Grass Medical 
Instrument, Quincy, MA, USA) (10 V/10 Hz; square wave pulse 1 ms duration, 10 second 
duration) confirmed the identity of the renal nerves. This nerve sheet and attendant connective 
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tissue surrounding the renal artery was stripped back carefully to denervate the kidney and any 
nerves remaining on the separated renal blood vessels destroyed through the application of 10% 
phenol in ethanol. Successful denervation was confirmed by the absence of a renal blanching 
response to nerve stimulation. It has been shown that the renal nerves can fully reinnervate after 
only 3-6 weeks, so the animals were subjected to repeated renal denervation every 3 weeks 
(Kline and Mercer, 1980; Mulder et al., 2013). 
At 18 weeks, the rats were anaesthetised with halothane and kidneys perfused in situ through 
the abdominal aorta with phosphate buffered saline (PBS; 4 °C) and the animal exsanguinated. 
The left kidney was removed and cut in half sagittally in PBS buffer (4 °C), and the cortical 
and medullary regions separated, snap frozen in liquid N2, and stored separately at -80 °C. The 
right kidney was perfuse-fixed in 10% neutral buffered formalin (NBF) for histological 
examination. Antigen retrieval was conducted on these kidney samples using a dedicated 
microwave system (Anatech Ltd, 1998) to heat the samples to 55 °C for five minutes in 10% 
NBF. The kidney sections were then sequentially dehydrated in 70-100% ethanol, cleared in 
xylene and embedded in paraffin wax by the Histology Service Unit, Department of Pathology, 
University of Otago.  
2.2 Noradrenaline Enzyme Linked Immunosorbent Assay 
(ELISA).  
2.2.1 Homogenate Preparation for ELISA 
Homogenates were prepared using cortical kidney samples stored at -80 °C which were sliced 
into small sections. These sections were then defrosted on ice, and homogenised using the 
Heidolph homogeniser at 500 rpm followed by 1100 rpm. Samples were then placed back onto 
ice immediately to reduce protein degradation. A homogenising buffer was used containing 
0.01 N HCl in the presence of 1 mM EDTA and 4 mM sodium metabisulfate in phosphate 
buffered saline. EDTA was essential to preserve the noradrenaline (NA) content. After cooling 
on ice, the homogenates were centrifuged at 4000 g and the supernatant collected and frozen at 
-80 °C for use in subsequent assays. This protocol was based on the ELISA manufacturer’s 
instructions (BA E-5200, Labor Diagnostika Nord). 
2.2.2 Noradrenaline ELISA 
To measure regional NA content within the cortex of the kidneys a commercial NA ELISA kit 
(BA E-5200, Labor Diagnostika Nord) was used on cortical kidney homogenates. The ELISA 
was carried out according to manufacturer’s instructions, with the NA content in the 
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homogenates determined against a standard curve. The primary NA antibody was covalently 
bound to a secondary antibody that was linked to an enzyme, which, upon addition of substrate, 
caused a visible signal that was quantified using a spectrophotometer.  
2.3 Immunohistochemistry 
2.3.1 Slice Preparation/Microtomy 
Paraffin wax embedded kidneys were sliced on the microtome to produce five μm thick 
sections, and flattened by transferring the sections onto a 30% ethanol solution for 15 seconds, 
followed by placing the sections onto the surface of a 40 °C water bath for one minute. This 
technique is an established method of removing any folds or tears in tissue sections that would 
otherwise adversely affect the quality of tissue staining. The sections were then attached onto 
adherent poly-L-lysine coated glass Superfrost microscope slides and dried overnight at 37 °C. 
Slides were stored at room temperature until use.  
2.3.2 Rehydration 
Rehydration was necessary to allow antibody probing of the slices. The paraffin wax was 
removed by xylene to thus allow eventual staining of the tissue, and a series of decreasing 
ethanol dilutions in distilled water ranging from 100% to 50% for four minutes each were 
performed to rehydrate the slice. The slice was then washed thrice for 10 minutes each with 50 
mM tris-buffered saline (pH 7.4) and a Dako pen used to draw a water-repelling barrier around 
the slice, thus allowing conservation of antibody solutions and chromogenic substrates, and a 
more uniform staining of the slice. 
2.3.3 Blocking 
Animal free blocker (SP-5053 Vector Laboratories, Inc. Bulingame, CA, USA) diluted 1:5 in 
deionised water was used to block non-specific binding of immunoglobulin (Ig) G, and was 
applied to the slice for two hours at room temperature in a humidified chamber to avoid 
evaporation of the slice. This humidification chamber was used in all incubation steps as drying 
of a slice during immunohistochemical staining introduces non-specific binding. The slice was 
then washed with tris buffered saline (TBS) containing 0.1% bovine serum albumin (BSA) for 





2.3.4 Primary Antibody 
The primary antibody was diluted in TBS with 0.1 % BSA (according to Table 1) and 50 μL 
was applied to each slice overnight (at least 15 hours) at 4 °C in a humidified chamber. A non-
specific binding control slice was also performed by substituting the primary antibody with the 
diluent of TBS containing 0.1% BSA.  
 
Antibody Host Species Dilution  Company/Source Method 
Podocin/NPHS2 Rabbit 1:40 Abcam, 
Cambridge, UK 
IHC 
Collagen I Rabbit 1:100/1:1000 Rockland, 
Gilbertsville, PA 
IHC/WB 
Collagen IV Rabbit 1:100/1:1000 Abcam, 
Cambridge, UK 
IHC/WB 
AT1R Mouse 1:20/1:1000 Abcam, 
Cambridge, UK 
IHC/WB 
Β-tubulin Rabbit 1:1000 Sigma-Aldrich, 
St Louis, MO 
WB 
 
Table 1: Antibodies used in immunohistochemistry and western blotting experiments. 
2.3.5 Endogenous Peroxidase Activity 
Commonly the secondary antibody used to detect the primary antibody was conjugated to a 
horse radish peroxidase (HRP) enzyme, and therefore any endogenous peroxidase activity of 
the tissue was quenched to reduce non-specific binding of the antibody. A solution of 3% 
hydrogen peroxide (H2O2) diluted in TBS was applied for 10 minutes to quench the endogenous 
peroxidase activity of the tissue and washed off thrice with TBS in 10 minute washes.  
2.3.6 Secondary Antibody 
A secondary antibody conjugated to HRP (Pierce, Rockford, IL) and raised against the host 
species of the primary antibody was diluted in TBS containing 0.1% bovine serum albumin 
(BSA) and incubated with the slice for 90 minutes at room temperature in a humidified 
chamber. Care was taken to ensure that the antibody solution was evenly distributed over the 
entire slice, and that no bubbles were present, as these could prevent even exposure to the entire 
slice. This was washed off three times with TBS in 10 minute washes.  
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2.3.7 3,3-Diaminobenzidine (DAB) Staining 
A 3,3-diaminobenzidine (DAB) substrate kit (VECTOR SK-4100) was used to stain the tissue 
at room temperature, with a nickel solution to stain grey-black in some cases. When DAB is in 
the presence of H2O2, it is a sensitive substrate for HRP and results in a chromogenic reaction, 
allowing visualisation of specific proteins as detected with the antibodies that have the HRP 
attached. According to manufacturer’s instructions, two drops of Buffer Stock, five drops of 
DAB Stock, two drops of H2O2, and two drops of nickel solution were added consecutively to 
five mL of distilled water, immediately prior to use. This was applied in the dark for two – ten 
minutes depending on the strength of staining, with uniform staining periods employed for each 
different protein staining. The substrate was washed off with distilled water.  
2.3.8 Nuclear Counterstain 
Following the DAB staining, haematoxylin provided by the Histology Service Unit, 
Department of Pathology, University of Otago, was applied for 10 seconds to stain the nuclei 
of renal cells purple without masking the DAB stain. The slices were then washed in cold 
running water for five minutes.  
2.3.9 Section Dehydration and Mounting 
The slices underwent dehydration using a series of six escalating ethanol dilutions in distilled 
water ranging from 50% to 100% for three minutes in each solution, and were cleared with 
xylene for 30 seconds. Coverslips were attached to the briefly air-dried slides with DPX 
mountant (containing a plasticiser distyrene, dissolved in toluene-xylene) and pressed down 
uniformly to avoid bubbles. The slides were then left to dry overnight and the dry excess DPX 
scraped off with a scalpel to allow visualisation of the slice under a microscope.  
2.3.10 Histological Examination and Quantitative analysis 
Sections were examined using a Nikon Eclipse microscope. Kidneys sections were examined 
regionally, and ten pictures taken randomly from both the cortex and medulla areas (five per 
region). 
Digital pixel counting conducted using Photoshop CS6 (Adobe Systems, San Jose, CA) carried 
out semi-quantification of the sections. A ratio of positive staining was calculated against the 
total background staining and expressed as a percentage of background. Results were analysed 
using GraphPad Prism v.6.  
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2.4 Western Blotting  
Western Blotting involves the electrophoretic movement of protein samples through an 
acrylamide gel. Proteins separate within the gel depending on their molecular weight, and are 
then transferred onto a polyvinylidene fluoride (PVDF) membrane to allow antibody probing 
and visualisation of expression of specific proteins.  
2.4.1 Homogenate Preparation for Western Blotting 
Homogenates were prepared using kidney cortical samples stored at -80 °C which were sliced 
into smaller sections. These sections were then defrosted on ice, and homogenised in RIPA 
(radio immuno precipitation assay) buffer with protease inhibitors PMSF and PI to reduce the 
extent of protein degradation by tissue proteases. The homogenate was then centrifuged for five 
minutes at 4 °C and 6000 g, and the supernatant stored in aliquots at -80 °C until used in 
Western Blotting analysis. The Bio-Rad DC Protein Assay kit (Bio-Rad, Hercules, CA, USA) 
was used to determine protein concentration of each homogenate.  
2.4.2 Protein Concentration Estimation 
Protein concentrations in these homogenates were calculated using the Bio-Rad DC Protein 
Assay (Bio-Rad, Hercules, CA), with a standard protein curve calculated from BSA (0 - 2.0 
mg/mL). This is a colorimetric assay to detect protein concentration following solubilisation, 
based on the method of Lowry. The protein reacts with an alkaline copper tartrate solution first, 
following which the copper-treated protein reacts with Folin reagent to create a reduced form 
of Folin reagent, which has a characteristic blue colour with maximum absorbance at 750 nm 
and minimum absorbance at 405 nm. After reading in the SpectraMaxPlus spectrophotometer 
(Molecular Devices, BioStrategy, Vic, Australia) with dedicated SoftMax Pro v 4.8 software, 
the sample concentrations were calculated against the standard curve, using a Pearson 
correlation coefficient (R2) of ≥ 0.99 (Lowry et al., 1951).  
2.4.3 Sample Preparation 
The Invitrogen Western Blotting System (Life TechnologiesTM, Carlsbad, CA, USA) was used 
in this study. Sample homogenates were prepared to a standard concentration of 2.5 mg/ml 
prior to Western analysis. The defrosted homogenate of cortical kidney sample was diluted in 
deionised water, NuPAGE® LDS Sample Buffer (Cat# NP0007, Invitrogen, Carlsbad, CA, 
USA) (to denature the proteins), and NuPAGE® Reducing Agent (Cat# NP0004, Invitrogen, 
Carlsbad, CA, USA) (to keep proteins in a reduced form) in a ratio of 6.5:2.5:1 as recommended 
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by the Invitrogen system instructions. For those proteins for which non-reducing conditions 
were recommended to maintain protein structure, sample buffer replaced the reducing agent. 
Samples were incubated at 70 °C for 10 minutes in the water bath to allow the proteins to unfold 
and dissociate.  
2.4.4 Protein Loading and Running 
A NuPAGE® 4-12% Bis-Tris Gel (Cat# NP0322BOX, Invitrogen, Carlsbad, CA, USA) was 
used for electrophoresis of most proteins analysed as the graded concentration of bis-
acrylamide in the resolving gel is designed to allow small - medium sized proteins to separate 
easily and accurately. After the comb was carefully extracted from the gel the samples were 
loaded into the Midi-Cell gel system in sodium dodecyl sulphate (SDS) running buffer. 
Antioxidant diluted in running buffer (1:400) was added to the inner chamber to create reducing 
conditions when recommended, as it migrates with the proteins to prevent oxidation of the 
protein, thus maintaining the proteins in a reduced state. Protein (25 μg) was loaded uniformly 
across each well. Novex Sharp Pre-stained Protein Standard (10 μL) was also loaded to allow 
estimation of band size. The gels then underwent electrophoresis at 200 V for 55 minutes or 
until the protein sample had migrated through the gel according to molecular weight.  
2.4.5 Transfer 
Two methods of transfer were employed, with most proteins detected undergoing dry-blot 
transfer. However with the larger sized proteins that seemed to be harder to transfer from the 
gel into the membrane, wet blot transfer was employed, with a slow, low voltage transfer to 
ensure crisp and complete protein transfer. 
2.4.5.1 Dry Blot Transfer 
The resolving gel was placed onto the polyvinylidene difluoride (PVDF) membrane (Bio-Rad, 
Hercules, CA) above the Anode Stack. Filter paper was placed upon the gel and the cathode 
stack on top. Bubbles of air were removed with a stainless steel roller before the stack was run 
at 20 V for seven minutes according to manufacturer’s recommendations.  
2.4.5.2 Wet Blot Transfer 
The resolving gel was placed onto the PVDF membrane that had been soaked first in methanol, 
and then transfer buffer. This was placed between filter paper and then placed between sponge 
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pads before running at 20 V for 18 hours at 4 °C. The entire transfer chamber was packed on 
ice to avoid the heat generated from the current melting the gel.  
Transfer was confirmed by using Ponceau S stain, which binds temporarily to protein and 
allows visualisation of the protein bands if successful transfer from the gel has occurred.  
2.4.6 Blocking 
The PVDF membrane was salvaged from the stack and blocked with either 5% milk powder in 
0.5% TTBS containing 0.1% BSA for 2 hours at room temperature, or 5% animal free-blocker 
in the same solution, when milk powder was not recommended for blocking. The membrane 
was washed and stored in TTBS at 4 °C until protein detection.  
2.4.7 Detection 
2.4.7.1 Primary Antibody 
Primary antibody diluted in TTBS with 0.1% BSA was applied to the membrane overnight (at 
least 15 hours) at 4 °C at various concentrations specific to the antibody as laid out in Table 1. 
This was washed out with four washes of TTBS at five minute intervals. Β-tubulin was used as 
a loading control.  
2.4.7.2 Secondary Antibody 
An HRP-conjugated secondary antibody (Pierce, Rockford, IL), diluted in TTBS with 0.1 % 
BSA was applied to the membrane for two hours at room temperature. This was washed out 
with TTBS for five minutes, followed by three washes with TBS at five minute intervals.  
2.4.7.3 Chemiluminescence 
The membrane was immersed in enhanced chemiluminescent substrate (SuperSignal West 
Dura Extended Duration Substrate; Pierce, Rockford, IL) at a 1:1 ratio for five minutes, before 
being placed between plastic sheets in a Hyperfilm cassette. Exposure was performed in the 
dark room using the GS-710 Calibrated Imaging Densitometer (Bio-Rad, Hercules, CA) 
2.4.8 Analysis 
The band to be analysed was identified by overlaying the film and the protein standard ladder. 
Data was analysed using Quantity One software. Data was shown as a ratio of the protein in 
question against the loading control of β-tubulin in the same sample.  
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2.5 Statistics 
All data was compared using an one-way ANOVA, or a two-way ANOVA with a Bonferroni 
post hoc test, using GraphPad Prism software v7 (GraphPad Software, San Diego, CA). A 






3.1 Renal Cortical Noradrenaline 
We first wanted to ascertain that the bilateral renal denervation surgeries had resulted in 
complete renal denervation. To check this, a NA ELISA was used to measure levels of NA in 
the cortex of the kidneys (Figure 5B). Noradrenaline content was measured to be 22.68 ± 1.61 
ng/mg protein in the normoglycaemic innervated (NGInx) group, with denervation causing a 
reduction to 1.07 ± 0.08 ng/mg protein in the normoglycaemic denervated (NGDnx) group. The 
diabetic innervated (DBInx) group had 1.6 fold NA expression compared to the NGInx group 
with 36.94 ± 2.58 ng/mg protein, and this was also reduced in the diabetic denervated (DBDnx) 




Figure 5: Noradrenaline content in the renal cortex of normoglycaemic and diabetic rats, with 
or without denervation. Noradrenaline content in the renal cortex was measured with an ELISA 
in renal cortical homogenates, and calculated off a standard curve with the calculated equation 
as seen in (A), which had an R2 value of 0.992.  Groups are normoglycaemic innervated 
(NGInx), normoglycaemic denervated (NGDnx), diabetic innervated (DBInx), and diabetic 
denervated (DBDnx). Noradrenaline content (B) was significantly reduced by renal denervation 
in both the NGDnx and DBDnx groups. Noradrenaline content was higher in the DBInx than 
in the NGInx renal cortical tissue, reflecting an increased sympathetic drive in the diabetic 
animals. Data is shown as mean ± SEM. n = 7-8 per group. ** p<0.01. *** p<0.001.  
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3.2 Renal Podocin Expression  
We then went on to measure the expression levels of podocin in the renal tissue. Podocin was 
measured using immunolabelling with anti-NPHS2 (podocin) antibody, and counterstained 
with haematoxylin, and graphed as percentage area podocin positive (Figure 6E). Podocin 
expression was measured to be 22.7 ± 4.12 % in the NGInx group, with denervation causing no 
significant change. The DBInx group had a threefold decrease in podocin expression compared 






Figure 6: Podocin expression in renal cortical sections of normoglycaemic and diabetic rats, 
with or without denervation. Podocin expression was quantified using immunolabelling with 
anti-NPHS2 (podocin) antibody, and counterstained with haematoxylin, in normoglycaemic 
innervated (NGInx) (A), normoglycaemic denervated (NGDnx) (B), diabetic innervated 
(DBInx) (C), and diabetic denervated (DBDnx) (D) tissue, and graphed as percentage area 
podocin positive (E). Podocin was significantly reduced in the DBInx tissue, with denervation 
restoring this to normoglycaemic levels. Data is shown as mean ± SEM. n = 7-8 per group. ** 
p<0.01 vs NGInx. ψ p<0.05 vs DBInx. Scale bar = 50 µm. 
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3.3 Renal Collagen I Expression 
Collagen I expression was measured via immunolabelling with anti-collagen I antibody, and 
counterstained with haematoxylin to visualise the localisation of the fibrotic molecule, and 
graphed as percentage area collagen I positive (Figure 7B). There was no difference in collagen 
I expression between the normoglycaemic groups. The DBInx group had a 1.9 fold increase in 
collagen I expression compared to the NGInx group, with denervation bringing this down to 





Figure 7: Collagen I expression in renal cortical and medullary sections of normoglycaemic and 
diabetic rats, with or without denervation. Collagen I localisation and expression was assessed 
using immunolabelling with anti-collagen I antibody, and counterstained with haematoxylin in 
normoglycaemic innervated (NGInx), normoglycaemic denervated (NGDnx), diabetic 
innervated (DBInx), and diabetic denervated (DBDnx) tissue, and graphed as percentage area 
collagen I positive (B). Collagen I was significantly increased in the DBInx tissue, with 
denervation restoring this to normoglycaemic levels. Data is shown as mean ± SEM. n = 7-8 
per group. *** p<0.001 vs NGInx. ψ ψ ψ p<0.001 vs DBInx. Arrows point to glomerular and 




Collagen I expression was further measured via immunoblotting with anti-collagen I antibody, 
and graphed as a ratio between collagen I and β-tubulin (loading control) (Figure 8B). With a 
similar pattern to the histological results, collagen I expression was doubled in expression in 
the DBInx group compared to the normoglycaemic groups. Denervation reduced this 
expression to normoglycaemic levels.  
 
Figure 8: Collagen I expression in the renal cortex of normoglycaemic and diabetic rats, with 
or without denervation. Collagen I expression in the renal cortex was measured using western 
immunoblotting with anti-collagen I antibody in renal cortical homogenates, and normalised 
against β-tubulin, in normoglycaemic innervated (NGInx), normoglycaemic denervated 
(NGDnx), diabetic innervated (DBInx), and diabetic denervated (DBDnx) tissue. These data 
were graphed as a collagen I/β-tubulin ratio (B), with a sample blot shown (A). Collagen I was 
significantly increased in the DBInx tissue, with denervation restoring this to normoglycaemic 
levels. Data is shown as mean ± SEM. n = 7-8 per group. * p<0.05 vs NGInx. ψ p<0.05 vs 
DBInx.  
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3.4 Renal Collagen IV Expression 
Collagen IV expression was seen via immunolabelling with anti-collagen IV antibody, and 
counterstained with haematoxylin to visualise the localisation of the fibrotic molecule (Figure 
9). There was weak labelling of collagen IV in the normoglycaemic innervated and denervated 
groups. In the DBInx groups there was strong staining observed within the glomeruli and the 





Figure 9: Collagen IV expression in renal cortical and medullary sections of normoglycaemic 
and diabetic rats, with or without denervation. Collagen IV localisation and expression was 
assessed using immunolabelling with anti-collagen IV antibody, and counterstained with 
haematoxylin in normoglycaemic innervated (NGInx), normoglycaemic denervated (NGDnx), 
diabetic innervated (DBInx), and diabetic denervated (DBDnx) tissue. Labelling was seen 
prominently in the DBInx glomerular structures, as well as the medullary tubules. n = 7-8 per 
group. Arrow points to glomerular staining. Scale bar = 50 µm. 
 
 44 
Collagen IV expression was further measured via immunoblotting with anti-collagen IV 
antibody, and graphed as a ratio between collagen IV and β-tubulin (loading control) (Figure 
10B). Collagen IV expression was threefold higher in expression in the DBInx group compared 
to the normoglycaemic groups. Denervation reduced this expression to normoglycaemic levels. 
 
Figure 10: Collagen IV expression in the renal cortex of normoglycaemic and diabetic rats, with 
or without denervation. Collagen IV expression in the renal cortex was measured using western 
immunoblotting with anti-collagen IV antibody in renal cortical homogenates, and normalised 
against β-tubulin, in normoglycaemic innervated (NGInx), normoglycaemic denervated 
(NGDnx), diabetic innervated (DBInx), and diabetic denervated (DBDnx) tissue. These data 
were graphed as a collagen IV/β-tubulin ratio (B), with a sample blot shown (A). Collagen IV 
was significantly increased in the DBInx tissue, with denervation restoring this to 
normoglycaemic levels. Data is shown as mean ± SEM. n = 7-8 per group. * p<0.05 vs NGInx. 
ψ p<0.05 vs DBInx.  
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3.5 Renal Angiotensin II Type 1 Receptor Expression 
Angiotensin II type 1 receptor expression in the cortex (Figure 11B) and medulla (Figure 11C) 
was measured via immunolabelling with anti-AT1R antibody, and counterstained with 
haematoxylin, with results graphed as percentage area AT1R positive. There was no difference 
in AT1R expression between the normoglycaemic groups. The DBInx group had a fourfold 
increase in AT1R expression compared to the NGInx group, with denervation bringing this 
down to normoglycaemic levels again in the cortex. In the medulla, the DBInx group had a 5.5 
fold increase in AT1R expression compared to the NGInx group, with denervation bringing this 




Figure 11: Angiotensin II type 1 receptor expression in renal cortex and medulla of 
normoglycaemic and diabetic rats, with or without denervation. Angiotensin II type 1 receptor 
expression was quantified using immunolabelling with anti-AT1R antibody, and counterstained 
with haematoxylin, in normoglycaemic innervated (NGInx), normoglycaemic denervated 
(NGDnx), diabetic innervated (DBInx), and diabetic denervated (DBDnx) tissue, and graphed 
as percentage area AT1R positive (B, C). Angiotensin II type 1 receptor expression was 
significantly increased in the DBInx tissue, with denervation restoring this to normoglycaemic 
levels. Data is shown as mean ± SEM. n = 7-8 per group. *** p<0.001 vs NGInx. Arrows point 
to epithelial layer of the collecting tubules. Scale bar = 50 µm. 
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Angiotensin II type 1 receptor expression was further measured via immunoblotting with anti-
AT1R antibody, and graphed as a ratio between AT1R and β-tubulin (loading control) (Figure 
12B). Angiotensin II type 1 receptor expression was not significantly different between all 
groups. 
 
Figure 12: Angiotensin II type 1 receptor expression in renal cortical tissue of normoglycaemic 
and diabetic rats, with or without denervation. Angiotensin II type 1 receptor expression in the 
renal cortex was measured using western immunoblotting with anti- AT1R antibody in renal 
cortical homogenates, and normalised against β-tubulin, in normoglycaemic innervated 
(NGInx), normoglycaemic denervated (NGDnx), diabetic innervated (DBInx), and diabetic 
denervated (DBDnx) tissue. These data were graphed as an AT1R /β-tubulin ratio (B), with a 
sample blot shown (A). Angiotensin II type 1 receptor was not significantly changed between 






4.1 General Discussion 
Bilateral renal denervation has been demonstrated to be effective in reducing blood pressure in 
models of hypertension (Winternitz et al., 1980; Alexander et al., 2005). Whilst this is a proven 
technique to treat such dysfunction, the development of anti-hypertensive pharmacological 
agents such as angiotensin converting enzyme inhibitors, and angiotensin receptor blockers 
reduced the need for further research into this field. However, the multiple side effects 
associated with these drug therapies have caused focus to shift towards other methods, and thus 
renal denervation has become a topic of interest. Studies have focused on the effect of renal 
denervation on hypertension, in hypertensive models, but our research is the first to investigate 
the effect of renal denervation on the contributions which are attributed to the presence of 
diabetes in addition to the hypertension.  
4.1.1 Summary  
Bilateral renal denervation was shown to effectively reduce the renal dysfunction and injury 
observed in the diabetic transgenic rat. When diabetes and hypertension were both present as 
co-morbidities, the kidney showed morphological changes such as a loss of podocin evident of 
glomerular damage and albuminuria (Yao et al., 2014), and broader changes including the 
deposition of fibrotic tissue throughout the kidney. These damaging effects are commonly 
observed in patients with renal disease, in particular those with DN (Fioretto and Mauer, 2007). 
Current pharmacological interventions are unable to alleviate these signs of damage (Gross et 
al., 2005), but the bilateral renal denervation performed in our study brought all markers back 
to normoglycaemic levels. Podocin, collagen I, and collagen IV were all restored to levels 
consistent with those seen in the normoglycaemic transgenic rats, with a reduction in podocin 
loss, a reduction in fibrosis, and a reduction in the expression of AT1R. The change in the region 
specific expression of AT1R in the proximal tubule and cortical and medullary collecting ducts, 
is thought to be indicative of a suppression or lack of activation of the renin-angiotensin system 
(Yoo et al., 2007), which in turn reduces hypertension (Mogensen et al., 2000) and renal 
sympathetic nerve activity. Inhibition of angiotensin even in the central nervous system can 
affect renal sympathetic tone, with studies showing blockade of angiotensin in the hypothalamic 






4.1.2 Animal Model 
The animal model used in this study was genetically altered to be spontaneously hypertensive 
(Mullins et al., 1990). This meant that the diabetes was an additional co-morbidity to 
hypertension, used to simulate the clinical setting as much as possible, with DN and heart 
disease often expressed together (Komici et al., 2018). Most patients with DN also suffer 
hypertension under various levels of pharmacological control (Anavekar et al., 2004), so we 
wanted to ensure that the renal denervation was assessed in a model of DN that is as realistically 
similar as possible to the clinical presentation. It was also important to observe the effect of 
renal denervation in the context of hypertension as it was most likely that clinically it would 
also be present, and hypertension would have individual and specific effects on the kidney, 
renin-angiotensin system, and sympathetic nerve activity.  
4.1.3 Surgical Procedure 
One important factor in our study was the timeframe in which we performed the surgical 
ablations of the renal nerves. The 12 week timeline ensured that any renal damage that we 
observed would be due to a combination of diabetes and hypertension, rather than just due to 
hypertension alone (Kelly et al., 1998). This is important to allow us to distinguish our study 
apart from those already published on the effect of denervation on hypertension alone. We 
chose to only use female rats as the male rats of this model had been shown to display an 
increased blood pressure early on development, with morphological changes observed in the 
kidney, as well as an increased mortality requiring daily dosing with ACE-inhibitors which 
would have compromised the results being assessed (Appelhoff et al., 2010; Bachmann et al., 
1992; Kelly et al., 1998). The female rats however showed a delayed onset of hypertension and 
had no signs of any renal damage or injury at four months of age (Bachmann et al., 1992; Kelly 
et al., 1998). We also ensured that the denervation was maintained, as rat renal nerves can 
regrow within 3-6 weeks, by repeated denervation surgeries every three weeks to ensure 
complete denervation for the study duration (Kline and Mercer, 1980; Mulder et al., 2013). 
4.2 Summary of Findings 
4.2.1 Renal Noradrenaline Content 
The degree to which the renal denervation surgery had been successful was measured via a 
global renal NA content assessment. The NA content was reduced to low levels in the 
normoglycaemic kidney after the bilateral denervation surgeries were performed. The diabetic 
innervated kidney tissue had a higher level of NA compared to the normoglycaemic innervated, 
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which reflects the increased renal sympathetic nerve activity observed in diabetics. The 
reduction again to low levels in the diabetic denervated group allows us to conclude that 
bilateral renal denervation obliterates this activity in both normoglycaemic, and 
hyperglycaemic kidneys, and this confirms that our surgical technique was successful in 
denervation. This was supported by results from other members of the lab in which tyrosine 
hydroxylase staining was reduced by denervation surgery (Yao et al., 2014). We can also see 
from these results that diabetic kidneys have an increased renal sympathetic nerve activity level 
compared to the normoglycaemic animals which thus results in various detrimental effects of 
diabetes on the kidneys, and supports our reasoning for investigating denervation as a therapy 
for DN (Klein et al., 2001; Klein et al., 2003; Campese et al., 1995; Nielson et al., 1999).  An 
increase in renal sympathetic nerve activity could potentially result in a sustained increase in 
sympathetic nerve activity throughout the rest of the body, in particular the cardiovascular 
system and the brain (Joles and Koomans 2004). Part of this could be due to a compensatory 
mechanism that attempts to protect the body from a decrease in cardiac output, often caused by 
the comorbidity of diabetic cardiomyopathy.  
Early studies undertaken in the hypertensive rat have shown that renal denervation will reduce 
the severity of hypertension, whilst also reducing the expression levels of NA in the posterior 
hypothalamic region of the brain (Bigazzi et al., 1994; Campese et al., 1995; Ye et al., 1997). 
This supports the supposition that an increase in renal sympathetic nerve activity observed in 
damaged or deteriorating kidneys causes an increase in systemic sympathetic nerve activity, as 
well as sympathetic nerve activity in the central nervous system. This would all combine to 
result in overall activation of sympathetic nerves, and through the combination of direct 
vasoconstrictive effects of the vasculature, as well as the resultant activation of the renin-
angiotensin system, hypertension would inevitably develop (Esler et al., 2006). It is also seen 
that bilateral renal denervation causes a reduction in blood pressure in animals with neurogenic 
hypertension, this supporting the reasoning that by reducing the sympathetic activity, 
hypertension, which is ultimately framed by renin-angiotensin system overactivation, can be 
reduced (Ye et al., 2002).  
4.2.2 Renal Podocin Expression 
Our results of podocin expression supported the hypothesis that podocyte function would be 
altered by diabetes in conjunction with hypertension, and improved by denervation. Renal 
filtration is carefully controlled by three components; the fenestrated capillary endothelium, the 
glomerular basement membrane, and the podocytes. The foot-like projections of podocytes 
which wrap around the glomerular capillaries form slits, resulting in a size dependent filtration 
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barrier. If the podocytes are reduced in number or size, the slits get wider, and therefore let 
more proteins and other molecules into the urine, and this dysfunction is often detected in 
patients by the presence of proteinuria (protein in the urine) (Tryggvason and Pettersson 2003). 
Podocin is a protein important in the function and structure of these podocytes, in particular the 
feet like projections, and a decrease in podocin results in a decrease in podocyte number and 
function. Various studies have investigated the changes in podocytes when in diabetes, as the 
integrity of the podocyte and thus the filtration barrier is a key component of DN (Yoo et al., 
2007). Cultured podocytes exposed to high glucose have displayed increased renin-angiotensin 
system activation, with increases in the levels of AT1R expressed in the podocytes directly (Yoo 
et al., 2007). Other studies have shown that an increase in reactive oxygen species caused by 
hyperglycaemia in diabetes can result in apoptosis in podocytes, and therefore a reduction in 
the number of functional podocytes in type 1 diabetic mice in the early stages of nephropathy 
(Susztaki et al., 2006). 
The expression of podocin was 22.7% in normoglycaemic kidney samples, and this was not 
altered by the bilateral renal denervation. However, the level of podocin was markedly reduced 
in the diabetic innervated samples, which would indicate a significant reduction in the filtration 
capability of the kidney in diabetes (Tryggvason and Pettersson 2003). This also indicates that 
the observed changes are due to the added factor of diabetes and not due to the underlying 
hypertension of the rat model, a finding supported by evidence that damage to the glomerulus 
was lessened by the sympathoplegic drug moxonidine in normotensive, non-diabetic patients, 
at levels below anti-hypertensive doses (Strojek et al., 2001). Podocin expression was increased 
by the bilateral renal denervation surgeries, returning to normoglycaemic levels. This is 
particularly promising as to the usefulness of the bilateral renal denervation as a surgical 
treatment for DN as the restoration of podocin can be assumed to also restore the renal filtration 
functionality. This was confirmed by other members of the laboratory team through the 
restoration of the glomerular filtration rate in the diabetic denervated group (Yao et al., 2014).  
The loss of podocin in the diabetic innervated group correlated with data from other members 
of the laboratory showing an increase in albuminuria which was attenuated by bilateral renal 
denervation (Yao et al., 2014). This link between a reduction of podocin expression in the 
glomerulus and the level of albuminuria is evident in other animals studies, as well as in human 
patients (Koop et al., 2003; Wu et al., 2008). Studies in cultured podocytes have shown that β-
adrenoceptor agonists applied to podocytes can increase the levels of intracellular calcium 
(Huber et al., 1998). This can directly alter the shape of the podocytes, as well as reduce the 
number of foot processes. Thus, we see that β-adrenoceptor stimulation can directly regulate 
the structure and functionality of podocytes, and can therefore extrapolate this regulatory effect 
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to be altered in times of increased renal sympathetic nerve activity, such as occurs in 
hypertension and DN.  
The results from these studies could mean that the increased levels of NA that we observed in 
the renal cortical tissue in the diabetic innervated could cause the decrease in podocin 
expression and thus mediate podocyte injury, further resulting in damage to the glomerular 
filtration barrier.  We observed that bilateral renal denervation attenuated the loss of podocin 
seen in innervated diabetics, and this would likely be due directly to the lack of sympathetic 
activation of the renal nerves. This is supported by earlier studies which showed renal 
denervation reduced the severity of glomerulosclerosis as well as decreasing blood pressure in 
hypertensive rats with chronic renal failure (Campese and Kogosov, 1995). This glomerular 
protection observed could also be caused by a reduction in blood pressure as this would 
decrease the renin-angiotensin system activation and therefore reduce the inputs on both the 
sympathetic inputs as well as the renin release. However, the glomerular protection observed 
cannot be wholly explained by the potential decrease in blood pressure as podocin was seen to 
be altered in animals without a corresponding alteration in blood pressure. It is also key that the 
normoglycaemic group did not have altered levels of podocin, meaning that the hypertension 
alone was not causing glomerular damage. Other studies support this finding with results 
showing that renal denervation can protect the glomerular structure and function without any 
reduction in blood pressure observed (Nagasu et al., 2010). Other groups used pharmacological 
agents to block renal sympathetic nerve activity in hypertensive rats, and found similar effects 
on glomerular function when the drugs were administered at levels which would not protect 
against hypertension (Amann et al., 2000; Gattone et al., 1990). There are β-adrenoceptors 
located within the glomerulus itself, and this makes it highly likely that renal sympathetic nerve 
activation directly interacts with glomerular structures and causes renal damage in conditions 
of high sympathetic tone (Boivin et al., 2001). 
4.2.3 Renal Fibrosis 
Renal cortical and medullary fibrosis is an established marker of renal dysfunction and 
deterioration (Sugimoto et al., 2007; Nangaku 2004), and our results confirmed this with an 
elevated level of collagen I observed. We measured collagen I expression in the diabetic 
innervated kidney to be twice that of the normoglycaemic sections, demonstrating further 
deterioration of the filtration barrier. However, the bilateral renal denervation reduced the levels 
of collagen I measured down to normoglycaemic levels. Collagen IV is important in the 
filtration barrier through the structural support of the basement membrane (Pӧschl et al., 2004). 
An increase in collagen IV deposition results in filtration dysfunction and further renal damage. 
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Our data showed that whilst collagen IV was minimally expressed in the normoglycaemic tissue 
sections, there was elevated expression in both the glomerular and medullary tubules regions 
of the diabetic innervated kidney. Bilateral renal denervation reduced this expression to 
normoglycaemic levels. Total expression of collagen IV was in line with the histological 
findings, with a significant increase in collagen IV deposition a likely cause of further renal 
dysfunction due to interstitial fibrosis, as well as structural and functional basement membrane 
issues. The reduction in total collagen IV expression in the denervated group is further evidence 
that the denervation is potentially therapeutic for DN. These results were similar in the total 
collagen I expression in the kidney samples, supporting our hypothesis that denervation reduces 
the fibrosis of the kidney in diabetics. Other studies investigated fibrosis and fibrotic markers 
in a rat model of renal inflammation treated with bilateral renal denervation, and found that 
renal injury markers such as albuminuria were reduced, whilst collagen IV and TGF-β 
expression were reduced also in the denervated rats (Veelken et al., 2008).  
Fibrosis in the kidney can be made up of different fibre types, but all types contribute to cause 
renal dysfunction and detrimental structural modification.  Collagen I is typically at low levels 
in the kidney, mainly involved in the maintenance of the basement membrane integrity along 
with collagen IV, and only in the renal interstitium, with little deposition in the glomerular 
structure (Yoshioka et al., 1990). However as renal disease progresses, collagen I is increased 
in expression, and can be observed in the medulla as a marker of interstitial fibrosis (Yoshioka 
et al., 1990).  The repeated applications of bilateral renal denervation caused suppression of 
this increase in collagen which reduced the level of fibrosis in the kidney overall. Previous work 
has shown that bilateral renal denervation can reduce the expression of TGF-1, a factor 
important in the regulation of collagen, and development of fibrosis (Veelken et al., 2008). It 
has also been demonstrated that the development of fibrosis involves both afferent and efferent 
renal nerves, and this supports our finding that bilateral renal denervation reduces fibrosis (Kim 
and Padanilam, 2013).  
It is also a possibility that the reduction in fibrosis is a result of a decreased degree of 
inflammation, a well known factor involved in renal diseases (Fornoni et al., 2008), including 
DN. Inflammation causes activation of multiple factors, and often leads to the deposition of 
collagen and therefore the development of fibrosis (Lee and Kalluri 2010). Inflammation would 
activate the release of renin from the juxtaglomerular apparatus, which would in turn result in 
extracellular matrix accumulation of collagen, as well as fibrosis and profibrosis factors caused 
by an increase of intrarenal angiotensin II in the renal tubules. Bilateral renal denervation could 
potentially reduce the renin release, which would then reduce the renin-angiotensin system 
mediated fibrosis development, as well as the TGF-1 mediated fibrosis. Other studies suggest 
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that AT1R receptors are activated by nuclear factor-κβ, an inflammatory factor, which in turn 
recruits other renal inflammatory cells, and regulates the formation of further fibrosis (Ruiz-
Ortega et al., 2006). 
These results show that bilateral renal denervation can specifically reduce the expression of 
collagen I and collagen IV in the kidney, thus reducing the levels of fibrosis, which is a typical 
molecular dysfunction associated with DN.  
4.2.4 Renin-Angiotensin System 
Diabetes is known to increase the circulating levels of angiotensin II, and this therefore 
increases the density of the AT1R in the renal collecting ducts, within 20 days of diabetes in a 
rat model (Harrison-Bernard et al., 2002; Kobori et al., 2013). Our study was longer than this 
and further showed that this increase in AT1R extended to the cortical and outer medullary 
collecting ducts. Our histological images showed an increased staining intensity in the diabetic 
innervated samples which was reduced in the diabetic denervated group, with differential 
staining between the cortical and medullary collecting tubules, as well as the extracellular 
matrix regions. There was no obvious change in expression in the normoglycaemic groups with 
or without denervation, and this suggests that hypertension is not solely responsible for the 
increase in AT1R region specific expression, but rather diabetes is the causative factor.  
Whilst immunohistochemistry showed localised changes in the expression pattern of AT1R, 
this was not reflected in the total expression as measured by western blotting. The expression 
was not significantly different amongst any of the groups when evaluated as total expression. 
This could potentially be due to the fact that AT1R expression was low in general, and whilst 
some areas in the diabetic innervated sections had an increased level of expression, this would 
have been obscured by the low expression in the rest of the kidney. In the future, this should be 
determined by using laser capture microdissection on specific regions of the kidney to try to 
differentiate any differences there.  
The decrease in localisation of AT1R in diabetic kidneys treated with bilateral renal denervation 
was important however, as inhibition of this receptor has been shown to be important in 
reducing renal glomerular injury (Lafayette et al., 1992). The level of renal vascular resistance 
is a key factor in kidney health, with a reduction in renal vascular resistance conducive to 
reduced intrarenal pressure, and improved glomerular filtration. The chronic administration of 
AT1R inhibition is known to reduce the renal vascular resistance in type 2 diabetic patients, 
along with a reduction in blood pressure (Fliser et al., 2005). Other studies have investigated 
alternative methods of renin-angiotensin system blockade, such as vitamin D, known to inhibit 
the renin-angiotensin system, which also resulted in a reduction in hypertension and improved 
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renal function, as well as reduced renal injury markers such as glomerular and tubulointerstitial 
damage, and proteinuria (Freundlich et al., 2008).  
4.2.5 Summary 
Our study shows that in the renin overexpressing transgenic rat, the renal sympathetic nerves 
are significantly important in the pathogenesis of DN. Hypertensive rats with diabetes were 
assumed to have DN based on various functional and molecular factors measured (Appelhoff 
et al., 2010). These kidneys had significantly more markers of renal distress, including a 
reduction in podocin affecting the integrity of the glomerular structure, increased fibrosis 
deposition resulting in further renal injury, and an increased renin-angiotensin system activity. 
Bilateral renal denervation did not affect the renal morphological markers, or the markers of 
disease progression in the normoglycaemic rats with underlying hypertension. This offers clear 
evidence that hypertension alone is not causing the kidney disease in the rats, as it is only when 
paired with diabetes that the markers of damage are increased. The diabetic animals had 
increased levels of glomerular structure proteins, as well as increased deposition of collagen I 
and collagen IV. The renin-angiotensin system was increased in activation, as evidenced by an 
increase in the localisation of AT1R in the kidney, although not globally. Bilateral renal 
denervation alleviated these changes in renal molecules, returning them to normoglycaemic 
levels, and thus resulting in a reduction in podocyte injury and fibrosis development. Further 
research will need to be carried out to ascertain the functionality of this technique. Before use 
in the clinic this technique will need to be further investigated to ascertain if the denervation 
has the same effects in an established case of DN, and to see if denervation offers better 
outcomes than the current pharmacological interventions. It is most likely that a combination 
therapy involving an ACE inhibitor with renal denervation would offer the best approach, with 
pharmacological agents targeting the renin-angiotensin system, and denervation targeting the 
sympathetic system (Hamar et al., 2007).  
4.3 Renal Denervation in Human Studies 
4.3.1 Symplicity HTN Trials 
4.3.1.1 Symplicity HTN-1 Trial 
The use of renal denervation as a tool for treating hypertension has been the source of much 
debate over the past decade. The early work from the 1970s which showed the potential that 
renal denervation could have led into several large studies, all of which aimed to test the safety 
and efficacy of the therapy. The Symplicity HTN-1 trial was the first of these major studies to 
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take place (Krum et al., 2014). This was the largest trial of its kind at the time and was a proof 
of concept carried out by a worldwide team. The trial consisted of an open-label study of 150 
patients, with 88 patients continuing follow up for 36 months. Patients with resistant 
hypertension on at least three anti-hypertensive drugs were renally denervated, and blood 
pressure measurements taken over three years showed significant decreases in the systolic 
blood pressure. 93% of patients at 36 months displayed a decrease of 10 mmHg or more, and 
77% of these had a sustained decrease of 20 mmHg or more. The trial garnered a great deal of 
research interest, but was a proof of concept trial only, with various flaws including the lack of 
a control group or sham. However, their aim was to test the changes in blood pressure along 
with an evaluation of the short-term and long-term safety in patients with considerable 
hypertensive disease, along with other co-morbidities. The trial showed that renal denervation 
was safe and effective in reducing blood pressure over a sustained period of time, and that the 
kidney did not functionally re-innervate, a key factor in the appropriateness of the technique. 
There was no significant effect of age, renal disease, or diabetes on the efficacy of the treatment, 
which potentially allows the development of this technique into treating disorders such as DN, 
as we have investigated (Krum et al., 2014). 
4.3.1.2 Symplicity HTN-2 Trial  
The investigating team continued on to research the use of the renal denervation technique in 
the Symplicity HTN-2 trial (Esler et al., 2010), where patients were selected in a similar manner 
to the previous study, but randomly allocated into either a renal denervation group, or a control 
group. It is worth noting that the control group was not a sham operation, but rather these 
patients maintained their previous pharmacological treatment regimes. The researchers were 
not blinded to the treatment groups whilst analysing data and this has also thrown some doubt 
onto the reliability of the data. Nevertheless, this study successfully showed the six month 
efficacy of the renal denervation technique, with 84% patients showing a reduction of 10 mmHg 
or more in blood pressure. This supported previous findings from the group, as well as other 
literature, with renal denervation purportedly a safe and efficacious method in which to treat 
resistant hypertension. The safety of the technique, coupled with the wide ranging positive 
benefits across various different patient classifications, such as age and diabetes status, showed 





4.3.1.3 Symplicity HTN-3 Trial 
The third hypertension trial yielded very different results than expected based off the previous 
two trials. Symplicity HTN-3 (Bakris et al., 2015) was a prospective, randomised control trial, 
and differed from Symplicity HTN-2 in that the control group was in fact a sham group, who 
underwent a sham renal denervation (renal angiogram). Subjects were blinded to their treatment 
until six months, and then those shams who were eligible could choose to undergo the 
denervation surgery. However, contrary to expectations, the renal denervation group did not 
show any difference in blood pressure reduction compared to the sham group after one year. 
This was completely at odds with the previous studies, both of which had shown a significant 
decrease in blood pressure which was sustained over time. The Symplicity HTN-3 trial 
however, was comparing denervated subjects to a sham group, and appeared to indicate that 
denervation did not reduce blood pressure over that of sham denervation. The study concluded 
that whilst the technique was safe to use, it was no more efficacious than a sham surgery (Bakris 
et al., 2015).  
4.3.2 Impact of Symplicity HTN-3 
The impact of the Symplicity HTN-3 trial has been wide ranging. Whilst slowing research into 
denervation immediately, groups interested in the potential of renal denervation continued to 
investigate both the potential for denervation, as well as the reliability of the Symplicity HTN 
trials. Various groups have looked into the Symplicity HTN-3 and the factors contributing to 
the credibility of results. A major issue with the trial is the stability of the medication taken by 
participants. Many anti-hypertensives take up to eight weeks to take full effect, but patients 
were being admitted to the study with dosing variability within that timeframe. Up to 20% of 
participants were not on stable medication regimes within six weeks of the study commencing. 
There were also inconsistencies in the types of medications used between the groups, with a 
significantly higher number of participants in the sham group prescribed aldosterone 
antagonists and vasodilators than in the renal denervation group. This makes it hard to attribute 
the decreases in blood pressure observed in the sham group to the sham surgery, as it is more 
probable that they are due to the increased pharmacological inhibition of the renin-angiotensin 
system in that group (Lobo et al., 2015).  
Unfortunately, the compliance to the pharmacological regimes was assessed only via the word 
of the participant, with no biochemical assays or tests performed to confirm the drug load in 
the system matched the participant’s drug diary (Lobo et al., 2015).  
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There was also a major issue seen with the intervention itself. The renal denervation procedure 
was carried out by a high number of interventionists, with 111 different people responsible for 
varying numbers of surgeries. One third (34%) of the interventionists carried out just one renal 
denervation, and only 26 people performed more than five procedures. The amount of 
variability introduced by this study design was therefore considerable, and hard to discount 
from the interpretation of the results. Other smaller studies previously performed in animals 
and humans have always involved fewer personnel responsible for the renal denervation 
technique, and this sudden increase in the number involved was a serious flaw in the study 
(Lobo et al., 2015).  
There was also concern surrounding the number of attempts at ablation in each patient. Whilst 
each patient had only one renal denervation procedure performed, the average number of times 
the ablation was attempted was 11.2 ± 2.8 per patient. This means that rather than have the 
intervention done one time per patient, the renal nerves were getting varying degrees of 
ablation, with no way of knowing whether this was resulting in a consistent level of ablation, 
or as is more likely a highly variable degree of ablation (Lobo et al., 2015).  
The study had a set protocol for the delivery of the renal denervation. Part of this involved 
obtaining renal ablation in all four quadrants of both renal arteries, with denervation lesions 
placed in a spiral manner down the length of the vessel. This would ensure the kidneys were 
fully denervated, and was put in place to reduce the chance of the artery healing with 
constricting scar tissue which would be likely if the lesions were placed circumferentially. 
However, of the 304 participants who were undergoing the renal denervation, only 19 of these 
had full delivery of the ablation to all four quadrants of both arteries as per the set protocol. 
This means only 6.25% of study participants received the desired renal ablation that was 
required in the protocol. These participants were associated with the greatest decreases in blood 
pressure, which brings the conclusion of Symplicity HTN-3 into serious doubt, as 93.75% of 
participants were not correctly or consistently renally ablated. The combination of poor surgical 
adherence to the ablation protocol and the high variability associated with the large number of 
interventionists used poses a serious question about the reliability and consistency of the results. 
(Lobo et al., 2015). 
4.3.3 SPYRAL Trials 
With these concerns raised over the study design of the Symplicity HTN-3 trial, the 
investigators moved into designing a more robust study in order to ascertain the efficacy or not 
of renal denervation on treating hypertension. The SPYRAL HTN-OFF MED trial investigated 
the effect of renal denervation in patients with resistant hypertension who were not on 
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medication for this (Townsend et al., 2017). The study was improved from the previous work, 
with a single-blinded, randomised, sham-control study involving fewer interventionists to carry 
out the procedure, and the use of a multi electrode catheter (Medtronic) which ablated the nerve 
in four different places at the same time. Participant adherence to the lack of anti-hypertensive 
medication was confirmed at 85.5% with urine analysis, and 24 hour ambulatory blood pressure 
measurements were used to compare groups. The sample size was small with only 80 patients 
involved for the proof of concept study, but there was a significant reduction in ambulatory 
blood pressure with systolic pressure 5.5 mmHg lower in the denervated group, and no 
difference observed in the sham group. The group concluded that renal denervation proved to 
lower blood pressure in patients with resistant hypertension who were not on any medication 
for this. The improvement in study design was promising and allowed research to move forward 
with the denervation procedure treatment for hypertension and other disorders (Townsend et 
al., 2017). 
The same group went on to investigate the renal denervation in a hypertensive population who 
were on controlled medication for the duration of the study. Similarly to the SPYRAL HTN-
OFF MED trial, patient adherence was confirmed using urine analysis, and efforts were taken 
to reduce the variability in technique and application of the denervation procedure. This study, 
known as SPYRAL HTN-ON MED trial, followed the participants for six months, and found 
that renal denervation lowered blood pressure consistently and effectively, whilst sham did not 
cause any discernible change. The ablation technique was found to be safe, and it is now 
concluded that this renal denervation technique can reduce blood pressure in resistant 
hypertension patients with or without anti-hypertensive medication. (Kandzari et al., 2018). 
Another study recently released, known as RADIANCE-HTN SOLO, has also investigated the 
use of an endovascular ultrasound renal denervation technique. A sham controlled, single blind 
trial is underway and the results at two months indicate a greater reduction in blood pressure 
with no adverse events in the denervated group compared to the controls. There is no difference 
in outcomes between the two different methods of renal ablation and this is promising as it 









The data shown in this thesis strongly supports the hypothesis that bilateral renal denervation 
both alleviates and attenuates the renal damage and signs of DN in a rat model of streptozotocin 
induced DN. Denervation was successful, as shown with the reduced renal NA observed, and 
denervation in the diabetic animals restored the levels of podocin, collagen I, and collagen IV 
back to normoglycaemic levels. The renin-angiotensin system was significantly activated by 
diabetes, and this was reduced by the renal denervation, as hypothesised, making it likely that 
the observed improvement in kidney molecular markers and fibrosis is due in part to altered 
signalling in the renin-angiotensin system. Further investigation is required to fully elucidate 
the mechanism of action, and the exact role of the renin-angiotensin system in this pathology.  
These recent clinical results combined with the data provided in this experimental pre-clinical 
study strongly support the use of catheter based renal denervation for the treatment of DN, and 
are supported by other data on functional improvements published by the laboratory (Yao et 
al., 2017). The technique is proving to be effective in treating hypertension in well controlled 
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